{ "$schema": "https://mydosage.org/schema/export/v1.json", "version": "1.1.0", "generatedAt": "2026-07-22T21:15:31.983Z", "license": { "id": "CC-BY-SA-4.0", "url": "https://creativecommons.org/licenses/by-sa/4.0/", "attribution": "Mydosage contributors" }, "counts": { "substances": 57, "products": 61, "conditions": 7, "profiles": 14, "protocols": 12, "forks": 13, "follows": 23, "adverseEventsApproved": 6 }, "substances": [ { "slug": "semaglutide", "name": "Semaglutide", "aliases": [ "Ozempic", "Wegovy", "Rybelsus" ], "family": "GLP-1 receptor agonist", "summary": "Long-acting GLP-1 analogue approved for type-2 diabetes and chronic weight management. The most rigorously studied peptide on this index.", "mechanism": "Agonist at the GLP-1 receptor; delays gastric emptying, increases glucose-dependent insulin secretion, suppresses appetite via central pathways.", "halfLife": "~7 days", "typicalDose": "0.25–2.4 mg/week, titrated", "routes": [ "Subcutaneous", "Oral" ], "evidenceTier": "human-rct", "contraindications": [ "Personal/family MTC", "MEN-2", "Pregnancy", "History of pancreatitis (caution)" ], "reportedUses": [ { "conditionSlug": "weight-management", "tier": "human-rct" }, { "conditionSlug": "addiction-cravings", "tier": "human-observational" }, { "conditionSlug": "eating-disorders", "tier": "anecdotal" } ], "citations": [ { "label": "Wilding et al., 2021 — STEP 1 — NEJM", "url": "https://pubmed.ncbi.nlm.nih.gov/33567185/" } ] }, { "slug": "tirzepatide", "name": "Tirzepatide", "aliases": [ "Mounjaro", "Zepbound" ], "family": "GIP / GLP-1 dual agonist", "summary": "Dual incretin receptor agonist with larger weight reduction than semaglutide in head-to-head trials.", "mechanism": "Co-agonist at GIP and GLP-1 receptors; delays gastric emptying, modulates appetite and glucose homeostasis.", "halfLife": "~5 days", "typicalDose": "2.5–15 mg/week, titrated", "routes": [ "Subcutaneous" ], "evidenceTier": "human-rct", "contraindications": [ "MTC", "MEN-2", "Pregnancy" ], "reportedUses": [ { "conditionSlug": "weight-management", "tier": "human-rct" } ], "citations": [ { "label": "Jastreboff et al., 2022 — SURMOUNT-1 — NEJM", "url": "https://pubmed.ncbi.nlm.nih.gov/35658024/" } ] }, { "slug": "liraglutide", "name": "Liraglutide", "aliases": [ "Saxenda", "Victoza" ], "family": "GLP-1 receptor agonist", "summary": "Daily GLP-1 analogue, first-in-class for chronic weight management. Older and shorter-acting than semaglutide.", "mechanism": "GLP-1 receptor agonist; albumin-binding extends half-life relative to native GLP-1.", "halfLife": "~13 h", "typicalDose": "0.6–3.0 mg/day", "routes": [ "Subcutaneous" ], "evidenceTier": "human-rct", "contraindications": [ "MTC", "MEN-2", "Pregnancy" ], "reportedUses": [ { "conditionSlug": "weight-management", "tier": "human-rct" } ], "citations": [ { "label": "Pi-Sunyer et al., 2015 — SCALE — NEJM", "url": "https://pubmed.ncbi.nlm.nih.gov/26132939/" } ] }, { "slug": "dulaglutide", "name": "Dulaglutide", "aliases": [ "Trulicity" ], "family": "GLP-1 receptor agonist", "summary": "Weekly GLP-1 analogue fused to an IgG4 Fc fragment for extended half-life. Approved for T2D and cardiovascular risk reduction.", "mechanism": "GLP-1 receptor agonist with Fc fragment for once-weekly dosing.", "halfLife": "~5 days", "typicalDose": "0.75–4.5 mg/week", "routes": [ "Subcutaneous" ], "evidenceTier": "human-rct", "contraindications": [ "MTC", "MEN-2", "Pregnancy" ], "reportedUses": [ { "conditionSlug": "weight-management", "tier": "human-observational" } ], "citations": [ { "label": "REWIND, 2019 — Lancet", "url": "https://pubmed.ncbi.nlm.nih.gov/31189511/" } ] }, { "slug": "exenatide", "name": "Exenatide", "aliases": [ "Byetta", "Bydureon" ], "family": "GLP-1 receptor agonist", "summary": "Synthetic version of exendin-4 (Gila monster). First-in-class GLP-1 agonist for T2D.", "mechanism": "GLP-1 receptor agonist; resistant to DPP-4 degradation.", "halfLife": "~2.4 h (IR), ~2 weeks (XR)", "typicalDose": "5–10 mcg BID or 2 mg/week", "routes": [ "Subcutaneous" ], "evidenceTier": "human-rct", "contraindications": [ "MTC", "MEN-2", "Severe renal impairment" ], "reportedUses": [ { "conditionSlug": "weight-management", "tier": "human-rct" } ], "citations": [ { "label": "DeFronzo et al., 2005 — Diabetes Care", "url": "https://pubmed.ncbi.nlm.nih.gov/15855581/" } ] }, { "slug": "retatrutide", "name": "Retatrutide", "aliases": [ "LY3437943" ], "family": "GIP / GLP-1 / glucagon triple agonist", "summary": "Triple-receptor agonist in late-stage trials with ~24% mean weight loss at 48 weeks. Not yet approved.", "mechanism": "Co-agonism at GIP, GLP-1, and glucagon receptors.", "halfLife": "~6 days", "typicalDose": "1–12 mg/week (trial)", "routes": [ "Subcutaneous" ], "evidenceTier": "human-rct", "contraindications": [ "Investigational — clinical trial only" ], "reportedUses": [ { "conditionSlug": "weight-management", "tier": "human-rct" } ], "citations": [ { "label": "Jastreboff et al., 2023 — NEJM", "url": "https://pubmed.ncbi.nlm.nih.gov/37366316/" } ] }, { "slug": "cagrilintide", "name": "Cagrilintide", "aliases": [ "AM833" ], "family": "Amylin analogue", "summary": "Long-acting amylin analogue investigated alone and combined with semaglutide (CagriSema) for weight loss.", "mechanism": "Amylin and calcitonin receptor agonist; slows gastric emptying and increases satiety.", "halfLife": "~7 days", "typicalDose": "0.16–2.4 mg/week (trial)", "routes": [ "Subcutaneous" ], "evidenceTier": "human-rct", "contraindications": [ "Investigational" ], "reportedUses": [ { "conditionSlug": "weight-management", "tier": "human-rct" } ], "citations": [ { "label": "Enebo et al., 2021 — Lancet", "url": "https://pubmed.ncbi.nlm.nih.gov/34324834/" } ] }, { "slug": "orforglipron", "name": "Orforglipron", "aliases": [ "LY3502970" ], "family": "Oral non-peptide GLP-1 agonist", "summary": "Small-molecule oral GLP-1 agonist in phase 3; no food/water restrictions unlike Rybelsus.", "mechanism": "Non-peptide GLP-1 receptor agonist.", "halfLife": "~29–49 h", "typicalDose": "3–45 mg/day (trial)", "routes": [ "Oral" ], "evidenceTier": "human-rct", "contraindications": [ "Investigational" ], "reportedUses": [ { "conditionSlug": "weight-management", "tier": "human-rct" } ], "citations": [ { "label": "Wharton et al., 2023 — NEJM", "url": "https://pubmed.ncbi.nlm.nih.gov/37367459/" } ] }, { "slug": "survodutide", "name": "Survodutide", "aliases": [ "BI 456906" ], "family": "GLP-1 / glucagon dual agonist", "summary": "Boehringer Ingelheim/Zealand dual agonist in late trials for obesity and MASH.", "mechanism": "Co-agonism at GLP-1 and glucagon receptors.", "halfLife": "~5 days", "typicalDose": "0.6–6.0 mg/week (trial)", "routes": [ "Subcutaneous" ], "evidenceTier": "human-rct", "contraindications": [ "Investigational" ], "reportedUses": [ { "conditionSlug": "weight-management", "tier": "human-rct" } ], "citations": [ { "label": "le Roux et al., 2024 — Lancet D&E", "url": "https://pubmed.ncbi.nlm.nih.gov/38437850/" } ] }, { "slug": "ipamorelin", "name": "Ipamorelin", "aliases": [], "family": "Growth hormone secretagogue", "summary": "Selective GH secretagogue with minimal effect on cortisol or prolactin. Reported for sleep and recovery.", "mechanism": "Ghrelin (GHS-R1a) receptor agonist; pulses endogenous GH release.", "halfLife": "~2 h", "typicalDose": "200–300 mcg, 1–3× daily", "routes": [ "Subcutaneous" ], "evidenceTier": "preclinical", "contraindications": [ "Active malignancy", "Pregnancy" ], "reportedUses": [ { "conditionSlug": "recovery-sleep", "tier": "anecdotal" } ], "citations": [ { "label": "Raun et al., 1998 — Eur J Endocrinol", "url": "https://pubmed.ncbi.nlm.nih.gov/9678537/" } ] }, { "slug": "cjc-1295-dac", "name": "CJC-1295 (with DAC)", "aliases": [ "DAC:GRF" ], "family": "GHRH analogue (long-acting)", "summary": "GHRH analogue with drug-affinity complex extending half-life to days. Sustained elevation of GH/IGF-1.", "mechanism": "GHRH receptor agonist; DAC binds albumin in vivo for extended exposure.", "halfLife": "~6–8 days", "typicalDose": "1–2 mg/week", "routes": [ "Subcutaneous" ], "evidenceTier": "preclinical", "contraindications": [ "Active malignancy", "Pregnancy" ], "reportedUses": [ { "conditionSlug": "recovery-sleep", "tier": "anecdotal" } ], "citations": [ { "label": "Teichman et al., 2006 — JCEM", "url": "https://pubmed.ncbi.nlm.nih.gov/16352683/" } ] }, { "slug": "cjc-1295-no-dac", "name": "CJC-1295 (no DAC)", "aliases": [ "Modified GRF (1-29)", "Mod GRF" ], "family": "GHRH analogue (short-acting)", "summary": "Short-acting GHRH analogue used to pulse GH in combination with ghrelin mimetics.", "mechanism": "GHRH receptor agonist without albumin-binding modification.", "halfLife": "~30 min", "typicalDose": "100 mcg, 1–3× daily", "routes": [ "Subcutaneous" ], "evidenceTier": "preclinical", "contraindications": [ "Active malignancy", "Pregnancy" ], "reportedUses": [ { "conditionSlug": "recovery-sleep", "tier": "anecdotal" } ], "citations": [ { "label": "Sinha et al., 2013 — JCEM", "url": "https://pubmed.ncbi.nlm.nih.gov/23472217/" } ] }, { "slug": "sermorelin", "name": "Sermorelin", "aliases": [ "GRF 1-29", "Geref" ], "family": "GHRH analogue", "summary": "Synthetic GHRH(1-29) historically marketed as Geref. Common in US anti-aging compounding.", "mechanism": "Endogenous GHRH receptor agonist; physiologic GH pulses.", "halfLife": "~10–20 min", "typicalDose": "100–500 mcg/night", "routes": [ "Subcutaneous" ], "evidenceTier": "human-rct", "contraindications": [ "Active malignancy", "Hypothyroidism (uncontrolled)" ], "reportedUses": [ { "conditionSlug": "recovery-sleep", "tier": "human-observational" } ], "citations": [ { "label": "Walker, 2006 — Clin Interv Aging", "url": "https://pubmed.ncbi.nlm.nih.gov/18046889/" } ] }, { "slug": "tesamorelin", "name": "Tesamorelin", "aliases": [ "Egrifta" ], "family": "GHRH analogue (stabilised)", "summary": "Stabilised GHRH analogue approved for HIV-associated lipodystrophy; reduces visceral adipose tissue.", "mechanism": "GHRH receptor agonist with N-terminal modification for stability.", "halfLife": "~26–38 min", "typicalDose": "2 mg/day", "routes": [ "Subcutaneous" ], "evidenceTier": "human-rct", "contraindications": [ "Active malignancy", "Pregnancy", "Hypopituitarism" ], "reportedUses": [ { "conditionSlug": "weight-management", "tier": "human-rct" } ], "citations": [ { "label": "Falutz et al., 2010 — NEJM", "url": "https://pubmed.ncbi.nlm.nih.gov/17890231/" } ] }, { "slug": "mk-677", "name": "MK-677", "aliases": [ "Ibutamoren", "Oratrope" ], "family": "Oral ghrelin mimetic", "summary": "Orally active non-peptide ghrelin mimetic. Sustained GH/IGF-1 elevation but increases appetite and water retention.", "mechanism": "GHS-R1a agonist; oral small molecule.", "halfLife": "~4–6 h", "typicalDose": "10–25 mg/day", "routes": [ "Oral" ], "evidenceTier": "human-rct", "contraindications": [ "CHF", "Diabetes (caution)", "Active malignancy" ], "reportedUses": [ { "conditionSlug": "recovery-sleep", "tier": "anecdotal" } ], "citations": [ { "label": "Nass et al., 2008 — Ann Intern Med", "url": "https://pubmed.ncbi.nlm.nih.gov/19017919/" } ] }, { "slug": "hexarelin", "name": "Hexarelin", "aliases": [], "family": "Growth hormone secretagogue", "summary": "Potent ghrelin mimetic, more cortisol and prolactin response than ipamorelin. Less used clinically.", "mechanism": "GHS-R1a agonist.", "halfLife": "~55 min", "typicalDose": "100–200 mcg, 2–3× daily", "routes": [ "Subcutaneous" ], "evidenceTier": "preclinical", "contraindications": [ "Pregnancy", "Active malignancy" ], "reportedUses": [ { "conditionSlug": "recovery-sleep", "tier": "anecdotal" } ], "citations": [ { "label": "Locatelli et al., 1994 — Endocrinology", "url": "https://pubmed.ncbi.nlm.nih.gov/7956983/" } ] }, { "slug": "ghrp-2", "name": "GHRP-2", "aliases": [], "family": "Growth hormone secretagogue", "summary": "Ghrelin mimetic stronger than ipamorelin; moderate cortisol/prolactin rise.", "mechanism": "GHS-R1a agonist.", "halfLife": "~15–60 min", "typicalDose": "100–300 mcg, 2–3× daily", "routes": [ "Subcutaneous" ], "evidenceTier": "preclinical", "contraindications": [ "Pregnancy", "Active malignancy" ], "reportedUses": [ { "conditionSlug": "recovery-sleep", "tier": "anecdotal" } ], "citations": [ { "label": "Bowers, 1996 — JCEM", "url": "https://pubmed.ncbi.nlm.nih.gov/8550726/" } ] }, { "slug": "ghrp-6", "name": "GHRP-6", "aliases": [], "family": "Growth hormone secretagogue", "summary": "First-generation ghrelin mimetic with marked hunger-stimulating effect.", "mechanism": "GHS-R1a agonist; potent appetite stimulation.", "halfLife": "~15–60 min", "typicalDose": "100–300 mcg, 2–3× daily", "routes": [ "Subcutaneous" ], "evidenceTier": "preclinical", "contraindications": [ "Pregnancy", "Active malignancy" ], "reportedUses": [ { "conditionSlug": "recovery-sleep", "tier": "anecdotal" } ], "citations": [ { "label": "Bowers, 1991 — Endocrinology", "url": "https://pubmed.ncbi.nlm.nih.gov/2026598/" } ] }, { "slug": "bpc-157", "name": "BPC-157", "aliases": [ "Body Protection Compound 157", "PL 14736" ], "family": "Gastric pentadecapeptide", "summary": "Synthetic 15-aa sequence derived from a gastric juice protein. Reported anecdotally for soft-tissue and tendon recovery.", "mechanism": "Modulates nitric oxide system, upregulates GH receptor; promotes angiogenesis preclinically.", "halfLife": "~30 min (subcutaneous, rodent)", "typicalDose": "200–500 mcg/day", "routes": [ "Subcutaneous", "Oral (stable form)" ], "evidenceTier": "preclinical", "contraindications": [ "Active malignancy (theoretical)", "Pregnancy — no human data" ], "reportedUses": [ { "conditionSlug": "tendon-injury", "tier": "anecdotal" }, { "conditionSlug": "joint-pain", "tier": "anecdotal" } ], "citations": [ { "label": "Sikiric et al., 2018 — Curr Pharm Des", "url": "https://pubmed.ncbi.nlm.nih.gov/29879879/" } ] }, { "slug": "tb-500", "name": "TB-500", "aliases": [ "Thymosin Beta-4 fragment" ], "family": "Actin-sequestering peptide", "summary": "Synthetic fragment of Thymosin β4. Reported for recovery; small clinical trials in cardiac and ophthalmic contexts.", "mechanism": "Binds G-actin; regulates cytoskeletal organisation; endothelial migration preclinically.", "halfLife": "~2–3 h", "typicalDose": "2–5 mg/week, divided", "routes": [ "Subcutaneous", "Intramuscular" ], "evidenceTier": "preclinical", "contraindications": [ "Active malignancy (theoretical)", "Pregnancy" ], "reportedUses": [ { "conditionSlug": "tendon-injury", "tier": "anecdotal" } ], "citations": [ { "label": "Goldstein et al., 2012 — Ann NY Acad Sci", "url": "https://pubmed.ncbi.nlm.nih.gov/23045969/" } ] }, { "slug": "thymosin-beta-4", "name": "Thymosin β4 (full)", "aliases": [ "TB4", "Timbetasin" ], "family": "Actin-sequestering peptide", "summary": "Full-length 43-aa Tβ4. Distinct from the TB-500 fragment; clinical trials in dry-eye and cardiac repair.", "mechanism": "G-actin sequestering; modulates inflammation and angiogenesis.", "halfLife": "~2 h", "typicalDose": "Investigational", "routes": [ "Subcutaneous", "Ophthalmic" ], "evidenceTier": "human-observational", "contraindications": [ "Pregnancy" ], "reportedUses": [ { "conditionSlug": "tendon-injury", "tier": "anecdotal" } ], "citations": [ { "label": "Sosne et al., 2010 — Ann NY Acad Sci", "url": "https://pubmed.ncbi.nlm.nih.gov/20536942/" } ] }, { "slug": "kpv", "name": "KPV", "aliases": [ "α-MSH(11-13)" ], "family": "Tripeptide (α-MSH fragment)", "summary": "C-terminal α-MSH tripeptide with anti-inflammatory action; investigated for IBD and skin inflammation.", "mechanism": "Inhibits NF-κB and pro-inflammatory cytokine signalling.", "halfLife": "Short", "typicalDose": "200–500 mcg/day (anecdotal)", "routes": [ "Oral", "Topical", "Subcutaneous" ], "evidenceTier": "preclinical", "contraindications": [ "Pregnancy" ], "reportedUses": [ { "conditionSlug": "joint-pain", "tier": "anecdotal" } ], "citations": [ { "label": "Dalmasso et al., 2008 — Gastroenterology", "url": "https://pubmed.ncbi.nlm.nih.gov/18242208/" } ] }, { "slug": "larazotide", "name": "Larazotide", "aliases": [ "AT-1001" ], "family": "Tight-junction modulator (octapeptide)", "summary": "Investigational tight-junction regulator for coeliac disease; reduces zonulin-mediated permeability.", "mechanism": "Antagonises zonulin-induced opening of intestinal tight junctions.", "halfLife": "Short (gut-restricted)", "typicalDose": "0.5–8 mg with meals (trial)", "routes": [ "Oral" ], "evidenceTier": "human-rct", "contraindications": [ "Pregnancy (no data)" ], "reportedUses": [], "citations": [ { "label": "Leffler et al., 2015 — Gastroenterology", "url": "https://pubmed.ncbi.nlm.nih.gov/26226577/" } ] }, { "slug": "ghk-cu", "name": "GHK-Cu", "aliases": [ "Copper Tripeptide-1" ], "family": "Copper-binding tripeptide", "summary": "Naturally occurring copper-binding tripeptide. Topical use studied for skin remodelling; injectable use is anecdotal.", "mechanism": "Modulates wound-healing gene expression; binds copper(II) with high affinity.", "halfLife": "Short (minutes, plasma)", "typicalDose": "1–2 mg/day (anecdotal, injectable)", "routes": [ "Topical", "Subcutaneous" ], "evidenceTier": "human-observational", "contraindications": [ "Wilson's disease", "Copper sensitivity" ], "reportedUses": [ { "conditionSlug": "recovery-sleep", "tier": "anecdotal" } ], "citations": [ { "label": "Pickart & Margolina, 2018 — Int J Mol Sci", "url": "https://pubmed.ncbi.nlm.nih.gov/29879733/" } ] }, { "slug": "argireline", "name": "Argireline", "aliases": [ "Acetyl Hexapeptide-3", "Acetyl Hexapeptide-8" ], "family": "Topical cosmetic hexapeptide", "summary": "Cosmetic hexapeptide marketed as a topical anti-wrinkle agent. Modest effect in controlled studies.", "mechanism": "Mimics SNAP-25 N-terminus; competitively inhibits SNARE assembly in vitro.", "halfLife": "Topical, not systemic", "typicalDose": "5–10% topical", "routes": [ "Topical" ], "evidenceTier": "human-observational", "contraindications": [ "None significant (topical)" ], "reportedUses": [], "citations": [ { "label": "Wang et al., 2013 — JCDS", "url": "https://pubmed.ncbi.nlm.nih.gov/23906223/" } ] }, { "slug": "matrixyl", "name": "Matrixyl", "aliases": [ "Palmitoyl Pentapeptide-4", "Pal-KTTKS" ], "family": "Topical cosmetic peptide", "summary": "Palmitoylated collagen fragment marketed for topical anti-aging. Increases collagen synthesis in vitro.", "mechanism": "Stimulates collagen I, III, and fibronectin synthesis in fibroblasts.", "halfLife": "Topical", "typicalDose": "3–5% topical", "routes": [ "Topical" ], "evidenceTier": "human-observational", "contraindications": [ "None significant" ], "reportedUses": [], "citations": [ { "label": "Robinson et al., 2005 — Int J Cosmet Sci", "url": "https://pubmed.ncbi.nlm.nih.gov/18492182/" } ] }, { "slug": "snap-8", "name": "SNAP-8", "aliases": [ "Acetyl Octapeptide-3" ], "family": "Topical cosmetic peptide", "summary": "Extended Argireline variant; same mechanism in vitro, longer sequence.", "mechanism": "SNAP-25 N-terminal mimetic.", "halfLife": "Topical", "typicalDose": "5–10% topical", "routes": [ "Topical" ], "evidenceTier": "anecdotal", "contraindications": [ "None significant" ], "reportedUses": [], "citations": [] }, { "slug": "melanotan-1", "name": "Melanotan I", "aliases": [ "Afamelanotide", "Scenesse" ], "family": "α-MSH analogue", "summary": "Linear α-MSH analogue (afamelanotide), approved as Scenesse for erythropoietic protoporphyria.", "mechanism": "Melanocortin-1 receptor agonist; stimulates eumelanin production.", "halfLife": "~30 min (free); implant releases over months", "typicalDose": "16 mg implant every 2 months", "routes": [ "Subcutaneous implant" ], "evidenceTier": "human-rct", "contraindications": [ "Pregnancy", "Active melanoma" ], "reportedUses": [], "citations": [ { "label": "Langendonk et al., 2015 — NEJM", "url": "https://pubmed.ncbi.nlm.nih.gov/26132941/" } ] }, { "slug": "melanotan-2", "name": "Melanotan II", "aliases": [ "MT-II" ], "family": "α-MSH analogue (cyclic)", "summary": "Cyclic α-MSH analogue, the parent of bremelanotide. Unapproved; significant adverse-event profile.", "mechanism": "Non-selective melanocortin receptor agonist (MC1, MC3, MC4, MC5).", "halfLife": "~33 min", "typicalDose": "Not recommended — adverse-event risk", "routes": [ "Subcutaneous" ], "evidenceTier": "preclinical", "contraindications": [ "Pregnancy", "Personal/family melanoma", "History of moles/dysplastic nevi" ], "reportedUses": [], "citations": [ { "label": "Hadley & Dorr, 2006 — Peptides", "url": "https://pubmed.ncbi.nlm.nih.gov/16356597/" } ] }, { "slug": "pt-141", "name": "PT-141", "aliases": [ "Bremelanotide", "Vyleesi" ], "family": "α-MSH analogue (MC4)", "summary": "Cyclic α-MSH analogue approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women.", "mechanism": "Melanocortin-4 receptor agonist; central pro-erectile/libido pathway.", "halfLife": "~2.7 h", "typicalDose": "1.75 mg, on-demand", "routes": [ "Subcutaneous" ], "evidenceTier": "human-rct", "contraindications": [ "Uncontrolled hypertension", "Cardiovascular disease" ], "reportedUses": [], "citations": [ { "label": "Kingsberg et al., 2019 — Obstet Gynecol", "url": "https://pubmed.ncbi.nlm.nih.gov/31403600/" } ] }, { "slug": "setmelanotide", "name": "Setmelanotide", "aliases": [ "Imcivree" ], "family": "α-MSH analogue (MC4 selective)", "summary": "MC4R-selective agonist approved for rare monogenic obesity (POMC, LEPR, BBS).", "mechanism": "Selective melanocortin-4 receptor agonist.", "halfLife": "~11 h", "typicalDose": "2–3 mg/day", "routes": [ "Subcutaneous" ], "evidenceTier": "human-rct", "contraindications": [ "Pregnancy", "Pre-existing depression (caution)" ], "reportedUses": [ { "conditionSlug": "weight-management", "tier": "human-rct" } ], "citations": [ { "label": "Clément et al., 2020 — Lancet D&E", "url": "https://pubmed.ncbi.nlm.nih.gov/33189156/" } ] }, { "slug": "selank", "name": "Selank", "aliases": [], "family": "Tuftsin analogue (anxiolytic)", "summary": "Russian synthetic heptapeptide marketed for anxiety; limited Western trials.", "mechanism": "Modulates GABA system and serotonin turnover; immunomodulatory.", "halfLife": "Short", "typicalDose": "250–500 mcg, 1–3× daily", "routes": [ "Intranasal", "Subcutaneous" ], "evidenceTier": "human-observational", "contraindications": [ "Pregnancy" ], "reportedUses": [], "citations": [ { "label": "Medvedev et al., 2015 — Bull Exp Biol Med", "url": "https://pubmed.ncbi.nlm.nih.gov/26033595/" } ] }, { "slug": "semax", "name": "Semax", "aliases": [], "family": "ACTH(4-10) analogue", "summary": "Russian synthetic heptapeptide derived from ACTH; nootropic and neuroprotective claims.", "mechanism": "Modulates BDNF, dopamine, and serotonin systems; neuroprotective in stroke models.", "halfLife": "Short", "typicalDose": "200–600 mcg, 1–3× daily", "routes": [ "Intranasal" ], "evidenceTier": "human-observational", "contraindications": [ "Pregnancy" ], "reportedUses": [], "citations": [ { "label": "Gusev et al., 2005 — Stroke", "url": "https://pubmed.ncbi.nlm.nih.gov/15919889/" } ] }, { "slug": "cerebrolysin", "name": "Cerebrolysin", "aliases": [], "family": "Porcine brain peptide complex", "summary": "Peptide mixture from pig brain; used in Europe and Asia for stroke and dementia. Not FDA-approved.", "mechanism": "Mixed neurotrophic and neuromodulatory effects.", "halfLife": "Variable", "typicalDose": "5–30 mL/day IV (clinical)", "routes": [ "Intravenous", "Intramuscular" ], "evidenceTier": "human-rct", "contraindications": [ "Epilepsy (caution)", "Severe renal impairment" ], "reportedUses": [], "citations": [ { "label": "Bornstein et al., 2018 — CNS Drugs", "url": "https://pubmed.ncbi.nlm.nih.gov/29696507/" } ] }, { "slug": "dihexa", "name": "Dihexa", "aliases": [ "PNB-0408", "N-hexanoic-Tyr-Ile-(6) aminohexanoic amide" ], "family": "Angiotensin IV analogue", "summary": "Investigational small peptide claimed to potentiate HGF/c-Met signalling. No human data.", "mechanism": "HGF/c-Met signal augmentation in preclinical models.", "halfLife": "Unknown (human)", "typicalDose": "Experimental", "routes": [ "Oral", "Topical (experimental)" ], "evidenceTier": "preclinical", "contraindications": [ "Active malignancy (theoretical, c-Met)", "No human safety data" ], "reportedUses": [], "citations": [ { "label": "Benoist et al., 2014 — JPET", "url": "https://pubmed.ncbi.nlm.nih.gov/24403093/" } ] }, { "slug": "fgl", "name": "FGL", "aliases": [ "FG Loop peptide" ], "family": "NCAM-derived peptide", "summary": "NCAM-derived mimetic studied in cognition and neuroinflammation models.", "mechanism": "FGFR activation via NCAM mimicry.", "halfLife": "Short", "typicalDose": "Experimental", "routes": [ "Subcutaneous (research)" ], "evidenceTier": "preclinical", "contraindications": [ "No human safety data" ], "reportedUses": [], "citations": [ { "label": "Secher et al., 2006 — Neuroscience", "url": "https://pubmed.ncbi.nlm.nih.gov/16513272/" } ] }, { "slug": "p21", "name": "P21", "aliases": [ "CNTFR fragment" ], "family": "CNTF-derived peptide", "summary": "Experimental neurogenic peptide. Anecdotal cognitive use; no human trials.", "mechanism": "CNTF receptor-mediated neurogenesis (preclinical).", "halfLife": "Short", "typicalDose": "Experimental", "routes": [ "Intranasal", "Subcutaneous" ], "evidenceTier": "preclinical", "contraindications": [ "No human safety data" ], "reportedUses": [], "citations": [ { "label": "Chohan et al., 2011 — J Alzheimers Dis", "url": "https://pubmed.ncbi.nlm.nih.gov/21971402/" } ] }, { "slug": "dsip", "name": "DSIP", "aliases": [ "Delta Sleep-Inducing Peptide" ], "family": "Nonapeptide (sleep modulator)", "summary": "Endogenous nonapeptide associated with delta-wave sleep. Effects on sleep architecture are inconsistent in human trials.", "mechanism": "Unclear; possible GABAergic and opioid modulation.", "halfLife": "~7 min", "typicalDose": "100–500 mcg pre-sleep", "routes": [ "Subcutaneous", "Intranasal" ], "evidenceTier": "human-observational", "contraindications": [ "Pregnancy" ], "reportedUses": [ { "conditionSlug": "recovery-sleep", "tier": "anecdotal" } ], "citations": [ { "label": "Schneider-Helmert & Schoenenberger, 1983 — Experientia", "url": "https://pubmed.ncbi.nlm.nih.gov/6873112/" } ] }, { "slug": "epitalon", "name": "Epitalon", "aliases": [ "Epithalon", "AEDG" ], "family": "Pineal tetrapeptide", "summary": "Russian synthetic pineal-gland tetrapeptide. Marketed for longevity; evidence largely Russian/in-house.", "mechanism": "Reported telomerase activation in cell culture; pineal axis modulation.", "halfLife": "Short", "typicalDose": "5–10 mg/day for 10–20 days, cyclic", "routes": [ "Subcutaneous" ], "evidenceTier": "preclinical", "contraindications": [ "Pregnancy", "Active malignancy (theoretical)" ], "reportedUses": [ { "conditionSlug": "recovery-sleep", "tier": "anecdotal" } ], "citations": [ { "label": "Khavinson et al., 2003 — Neuroendocrinol Lett", "url": "https://pubmed.ncbi.nlm.nih.gov/14523355/" } ] }, { "slug": "thymosin-alpha-1", "name": "Thymosin α1", "aliases": [ "Zadaxin", "Tα1" ], "family": "Thymic peptide (28-aa)", "summary": "Thymic-origin peptide marketed as Zadaxin in 30+ countries (not US) for chronic hepatitis B/C and as adjuvant.", "mechanism": "Modulates T-cell maturation and innate immunity via TLR signalling.", "halfLife": "~2 h", "typicalDose": "1.6 mg, 2× weekly", "routes": [ "Subcutaneous" ], "evidenceTier": "human-rct", "contraindications": [ "Active organ transplant (caution — immunostimulation)" ], "reportedUses": [], "citations": [ { "label": "Camerini & Garaci, 2010 — Ann NY Acad Sci", "url": "https://pubmed.ncbi.nlm.nih.gov/20536926/" } ] }, { "slug": "thymulin", "name": "Thymulin", "aliases": [ "FTS" ], "family": "Zinc-dependent thymic peptide", "summary": "Zinc-bound thymic peptide with immunomodulatory and analgesic properties in animal models.", "mechanism": "Zinc-dependent modulation of T-cell differentiation.", "halfLife": "Short", "typicalDose": "Experimental", "routes": [ "Subcutaneous" ], "evidenceTier": "preclinical", "contraindications": [ "No human safety data" ], "reportedUses": [], "citations": [ { "label": "Dardenne, 2002 — Eur J Clin Microbiol", "url": "https://pubmed.ncbi.nlm.nih.gov/12172783/" } ] }, { "slug": "ss-31", "name": "SS-31", "aliases": [ "Elamipretide", "Bendavia", "MTP-131" ], "family": "Mitochondrial-targeted tetrapeptide", "summary": "Cardiolipin-binding tetrapeptide investigated for mitochondrial disease, heart failure, and dry AMD.", "mechanism": "Binds inner-mitochondrial cardiolipin; stabilises respiratory chain and reduces ROS.", "halfLife": "~2–3 h", "typicalDose": "40 mg/day (clinical)", "routes": [ "Subcutaneous" ], "evidenceTier": "human-rct", "contraindications": [ "Pregnancy" ], "reportedUses": [], "citations": [ { "label": "Karaa et al., 2018 — Neurology", "url": "https://pubmed.ncbi.nlm.nih.gov/29980635/" } ] }, { "slug": "mots-c", "name": "MOTS-c", "aliases": [], "family": "Mitochondrial-derived peptide (16-aa)", "summary": "Mitochondrially-encoded peptide implicated in insulin sensitisation and metabolic regulation.", "mechanism": "AMPK activation; folate/methionine cycle modulation.", "halfLife": "Short", "typicalDose": "Experimental", "routes": [ "Subcutaneous" ], "evidenceTier": "preclinical", "contraindications": [ "No human safety data" ], "reportedUses": [], "citations": [ { "label": "Lee et al., 2015 — Cell Metab", "url": "https://pubmed.ncbi.nlm.nih.gov/25738459/" } ] }, { "slug": "humanin", "name": "Humanin", "aliases": [], "family": "Mitochondrial-derived peptide (24-aa)", "summary": "Mitochondrial-encoded peptide with cytoprotective effects in neurons.", "mechanism": "Binds Bax to inhibit apoptosis; activates STAT3.", "halfLife": "Short", "typicalDose": "Experimental", "routes": [ "Subcutaneous" ], "evidenceTier": "preclinical", "contraindications": [ "No human safety data" ], "reportedUses": [], "citations": [ { "label": "Yen et al., 2013 — Trends Endocrinol Metab", "url": "https://pubmed.ncbi.nlm.nih.gov/23541159/" } ] }, { "slug": "kisspeptin-10", "name": "Kisspeptin-10", "aliases": [ "KP-10" ], "family": "Hypothalamic peptide", "summary": "GnRH-releasing kisspeptin fragment; investigated for HPG-axis stimulation and fertility.", "mechanism": "KISS1R agonist; triggers GnRH pulsatility.", "halfLife": "Very short (minutes)", "typicalDose": "Experimental", "routes": [ "Subcutaneous", "IV" ], "evidenceTier": "human-rct", "contraindications": [ "Pregnancy", "Hormone-sensitive malignancy" ], "reportedUses": [], "citations": [ { "label": "Abbara et al., 2015 — JCEM", "url": "https://pubmed.ncbi.nlm.nih.gov/26447969/" } ] }, { "slug": "gonadorelin", "name": "Gonadorelin", "aliases": [ "GnRH" ], "family": "GnRH decapeptide", "summary": "Synthetic GnRH used clinically for diagnostic testing and HPG stimulation.", "mechanism": "GnRH receptor agonist; pulsatile use maintains LH/FSH; continuous use suppresses.", "halfLife": "~10–40 min", "typicalDose": "100 mcg pulsatile or 100 mcg test dose", "routes": [ "Subcutaneous", "IV" ], "evidenceTier": "human-rct", "contraindications": [ "Hormone-sensitive tumours", "Pregnancy" ], "reportedUses": [], "citations": [ { "label": "Belchetz et al., 1978 — Science", "url": "https://pubmed.ncbi.nlm.nih.gov/100024/" } ] }, { "slug": "hcg", "name": "HCG", "aliases": [ "Human chorionic gonadotropin", "Pregnyl", "Ovidrel" ], "family": "Glycoprotein hormone", "summary": "Glycoprotein hormone used for ovulation induction and male hypogonadism. Strictly clinical.", "mechanism": "LH receptor agonist; stimulates ovarian steroidogenesis and testicular Leydig cells.", "halfLife": "~24–36 h", "typicalDose": "500–5000 IU per protocol", "routes": [ "Subcutaneous", "Intramuscular" ], "evidenceTier": "human-rct", "contraindications": [ "Hormone-sensitive tumours", "Pregnancy" ], "reportedUses": [], "citations": [ { "label": "FDA — Pregnyl label", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/017016s033lbl.pdf" } ] }, { "slug": "oxytocin", "name": "Oxytocin", "aliases": [ "Pitocin", "Syntocinon" ], "family": "Nonapeptide hormone", "summary": "Posterior pituitary nonapeptide. Clinical use for labour induction; off-label intranasal use for social/anxiety modulation.", "mechanism": "OXT receptor agonist; uterine contraction and central social/affective modulation.", "halfLife": "~1–6 min (IV)", "typicalDose": "Clinical only", "routes": [ "IV", "Intranasal (off-label)" ], "evidenceTier": "human-rct", "contraindications": [ "Pregnancy outside labour induction", "Cardiovascular disease (caution)" ], "reportedUses": [], "citations": [ { "label": "MacDonald et al., 2011 — Psychoneuroendocrinology", "url": "https://pubmed.ncbi.nlm.nih.gov/21208749/" } ] }, { "slug": "aod-9604", "name": "AOD-9604", "aliases": [ "hGH 177-191" ], "family": "GH fragment (C-terminal)", "summary": "Modified hGH 177-191 fragment originally trialled for obesity; missed endpoints in phase 3.", "mechanism": "Claimed lipolytic action via β3-adrenergic pathway; mechanism contested.", "halfLife": "Short", "typicalDose": "250–500 mcg/day", "routes": [ "Subcutaneous", "Oral" ], "evidenceTier": "human-rct", "contraindications": [ "Pregnancy" ], "reportedUses": [ { "conditionSlug": "weight-management", "tier": "human-rct" } ], "citations": [ { "label": "Heffernan et al., 2001 — Endocrinology", "url": "https://pubmed.ncbi.nlm.nih.gov/11606465/" } ] }, { "slug": "fragment-176-191", "name": "Fragment 176-191", "aliases": [ "HGH Frag 176-191" ], "family": "GH fragment (C-terminal)", "summary": "Related GH C-terminal fragment widely sold as a weight-loss peptide. Clinical evidence weak.", "mechanism": "Claimed lipolytic via β3-adrenergic activation; preclinical only.", "halfLife": "Short", "typicalDose": "250–500 mcg/day (anecdotal)", "routes": [ "Subcutaneous" ], "evidenceTier": "preclinical", "contraindications": [ "Pregnancy" ], "reportedUses": [], "citations": [] }, { "slug": "5-amino-1mq", "name": "5-Amino-1MQ", "aliases": [], "family": "Small-molecule NNMT inhibitor", "summary": "Small-molecule NNMT inhibitor sold alongside peptides; preclinical lipolysis and metabolic effects.", "mechanism": "Selective NNMT inhibition; raises NAD+ and SAM.", "halfLife": "~2 h", "typicalDose": "50–150 mg/day (anecdotal)", "routes": [ "Oral" ], "evidenceTier": "preclinical", "contraindications": [ "Pregnancy", "No human safety data" ], "reportedUses": [ { "conditionSlug": "weight-management", "tier": "anecdotal" } ], "citations": [ { "label": "Neelakantan et al., 2017 — Biochem Pharmacol", "url": "https://pubmed.ncbi.nlm.nih.gov/29074052/" } ] }, { "slug": "tesofensine", "name": "Tesofensine", "aliases": [ "NS2330" ], "family": "Triple monoamine reuptake inhibitor (small molecule)", "summary": "Investigational triple-reuptake inhibitor for obesity. Not a peptide — flagged for completeness because it is sold by RUO suppliers.", "mechanism": "Serotonin, noradrenaline, dopamine reuptake inhibition.", "halfLife": "~9 days", "typicalDose": "0.25–1 mg/day (trial)", "routes": [ "Oral" ], "evidenceTier": "human-rct", "contraindications": [ "Cardiovascular disease", "Psychiatric history" ], "reportedUses": [ { "conditionSlug": "weight-management", "tier": "human-rct" } ], "citations": [ { "label": "Astrup et al., 2008 — Lancet", "url": "https://pubmed.ncbi.nlm.nih.gov/18950853/" } ] }, { "slug": "adipotide", "name": "Adipotide", "aliases": [ "FTPP" ], "family": "Pro-apoptotic chimeric peptide", "summary": "Chimeric peptide targeting white-adipose vasculature. Phase 1 in obese humans; renal toxicity signal.", "mechanism": "Targets prohibitin on adipose endothelium and induces apoptosis.", "halfLife": "Short", "typicalDose": "Investigational", "routes": [ "Subcutaneous" ], "evidenceTier": "human-observational", "contraindications": [ "Renal impairment", "Pregnancy" ], "reportedUses": [ { "conditionSlug": "weight-management", "tier": "human-observational" } ], "citations": [ { "label": "Kolonin et al., 2004 — Nat Med", "url": "https://pubmed.ncbi.nlm.nih.gov/15170216/" } ] }, { "slug": "igf-1-lr3", "name": "IGF-1 LR3", "aliases": [ "Long R3 IGF-1" ], "family": "Insulin-like growth factor analogue", "summary": "Long-acting IGF-1 analogue with reduced IGFBP binding. Widely sold by RUO suppliers.", "mechanism": "IGF-1R agonist with extended half-life.", "halfLife": "~20–30 h", "typicalDose": "20–100 mcg/day (anecdotal)", "routes": [ "Subcutaneous" ], "evidenceTier": "preclinical", "contraindications": [ "Active malignancy", "Diabetic retinopathy", "Pregnancy" ], "reportedUses": [], "citations": [ { "label": "Tomas et al., 1993 — JCE", "url": "https://pubmed.ncbi.nlm.nih.gov/8467344/" } ] }, { "slug": "igf-1-des", "name": "IGF-1 DES", "aliases": [ "DES(1-3) IGF-1" ], "family": "Insulin-like growth factor analogue", "summary": "Short-acting IGF-1 analogue with high potency at sites of injection.", "mechanism": "IGF-1R agonist; reduced IGFBP affinity allows localised action.", "halfLife": "~20–30 min", "typicalDose": "30–100 mcg/day", "routes": [ "Subcutaneous" ], "evidenceTier": "preclinical", "contraindications": [ "Active malignancy", "Hypoglycaemia risk" ], "reportedUses": [], "citations": [] }, { "slug": "mecasermin", "name": "Mecasermin", "aliases": [ "Increlex" ], "family": "Recombinant human IGF-1", "summary": "Recombinant hIGF-1 approved for severe primary IGF-1 deficiency.", "mechanism": "IGF-1R agonist; replaces deficient endogenous IGF-1.", "halfLife": "~5.8 h", "typicalDose": "0.04–0.12 mg/kg BID", "routes": [ "Subcutaneous" ], "evidenceTier": "human-rct", "contraindications": [ "Active malignancy", "Closed epiphyses (for growth)", "Hypoglycaemia risk" ], "reportedUses": [], "citations": [ { "label": "FDA — Increlex label", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021839s003lbl.pdf" } ] }, { "slug": "follistatin-344", "name": "Follistatin-344", "aliases": [ "FST-344" ], "family": "Myostatin/activin antagonist", "summary": "Soluble follistatin isoform sequestering myostatin and activin. Gene-therapy work in trials; injectable peptide use is anecdotal.", "mechanism": "Sequesters myostatin/activin from receptor binding.", "halfLife": "Variable", "typicalDose": "Anecdotal", "routes": [ "Subcutaneous" ], "evidenceTier": "preclinical", "contraindications": [ "Pregnancy", "No human safety data" ], "reportedUses": [], "citations": [ { "label": "Lee et al., 2010 — PNAS", "url": "https://pubmed.ncbi.nlm.nih.gov/20064942/" } ] } ], "products": [ { "slug": "wegovy", "name": "Wegovy", "brandName": "Wegovy", "manufacturer": "Novo Nordisk", "vendor": "Novo Nordisk", "substanceSlugs": [ "semaglutide" ], "strengthMg": 2.4, "strengthUnit": "mg", "packSize": "Pre-filled pen, 4 doses", "doseLabel": "0.25 / 0.5 / 1.0 / 1.7 / 2.4 mg pen", "jurisdiction": "US / EU / UK", "category": "medicine", "regulatoryStatus": "FDA-approved · EMA · MHRA", "approvedFor": [ "Chronic weight management", "Cardiovascular risk reduction" ], "prescriptionOnly": true, "rxUrl": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s015lbl.pdf", "coaStatus": "verified", "provenance": 100, "quality": 88, "provenanceN": 50, "qualityN": 1200, "notes": "Novo Nordisk pen; full pharmacopeial QC; covered by Medicare in qualifying patients (2024).", "imageUrl": "/pens/wegovy-2-4.png", "makerSlug": "novo-nordisk", "accentColor": "#0A4DA0", "penClicksEnabled": true, "variants": [ { "label": "0.25 mg", "strengthMg": 0.25, "strengthUnit": "mg", "imageUrl": "/pens/wegovy-0-25.png", "color": "#9CA3AF", "penTotalMg": 1, "clickMg": 0.0125, "fullDoseClicks": 20, "dosesPerPen": 4 }, { "label": "0.5 mg", "strengthMg": 0.5, "strengthUnit": "mg", "imageUrl": "/pens/wegovy-1.png", "color": "#5BB3E0", "penTotalMg": 2, "clickMg": 0.025, "fullDoseClicks": 20, "dosesPerPen": 4 }, { "label": "1.0 mg", "strengthMg": 1, "strengthUnit": "mg", "imageUrl": "/pens/wegovy-1.png", "color": "#3FA85B", "penTotalMg": 4, "clickMg": 0.05, "fullDoseClicks": 20, "dosesPerPen": 4 }, { "label": "1.7 mg", "strengthMg": 1.7, "strengthUnit": "mg", "imageUrl": "/pens/wegovy-1-7.png", "color": "#E89A2B", "penTotalMg": 6.8, "clickMg": 0.085, "fullDoseClicks": 20, "dosesPerPen": 4 }, { "label": "2.4 mg", "strengthMg": 2.4, "strengthUnit": "mg", "imageUrl": "/pens/wegovy-2-4.png", "color": "#C2185B", "penTotalMg": 9.6, "clickMg": 0.12, "fullDoseClicks": 20, "dosesPerPen": 4 } ] }, { "slug": "ozempic", "name": "Ozempic", "brandName": "Ozempic", "manufacturer": "Novo Nordisk", "vendor": "Novo Nordisk", "substanceSlugs": [ "semaglutide" ], "strengthMg": 2, "strengthUnit": "mg", "packSize": "Pre-filled pen, 4 doses", "doseLabel": "0.25 / 0.5 / 1.0 / 2.0 mg pen", "jurisdiction": "US / EU / UK", "category": "medicine", "regulatoryStatus": "FDA-approved · EMA · MHRA", "approvedFor": [ "Type 2 diabetes", "Cardiovascular risk reduction in T2D" ], "prescriptionOnly": true, "rxUrl": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209637s023lbl.pdf", "coaStatus": "verified", "provenance": 100, "quality": 85, "provenanceN": 50, "qualityN": 980, "notes": "Same molecule as Wegovy; on-label for T2D rather than weight management.", "imageUrl": "/pens/ozempic-1.png", "makerSlug": "novo-nordisk", "accentColor": "#1B4FA0", "penClicksEnabled": true, "variants": [ { "label": "0.25 / 0.5 mg", "strengthMg": 0.5, "strengthUnit": "mg", "imageUrl": "/pens/ozempic-0-5.png", "color": "#D5403B", "penTotalMg": 2, "clickMg": 0.0125, "fullDoseClicks": 20, "dosesPerPen": 4 }, { "label": "1.0 mg", "strengthMg": 1, "strengthUnit": "mg", "imageUrl": "/pens/ozempic-1.png", "color": "#1B4FA0", "penTotalMg": 4, "clickMg": 0.05, "fullDoseClicks": 20, "dosesPerPen": 4 }, { "label": "2.0 mg", "strengthMg": 2, "strengthUnit": "mg", "imageUrl": "/pens/ozempic-1.png", "color": "#7A1B1B", "penTotalMg": 8, "clickMg": 0.1, "fullDoseClicks": 20, "dosesPerPen": 4 } ] }, { "slug": "rybelsus", "name": "Rybelsus", "brandName": "Rybelsus", "manufacturer": "Novo Nordisk", "vendor": "Novo Nordisk", "substanceSlugs": [ "semaglutide" ], "strengthMg": 14, "strengthUnit": "mg", "packSize": "30 tablets", "doseLabel": "3 / 7 / 14 mg oral tablet", "jurisdiction": "US / EU / UK", "category": "medicine", "regulatoryStatus": "FDA-approved · EMA · MHRA", "approvedFor": [ "Type 2 diabetes" ], "prescriptionOnly": true, "rxUrl": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213051s010lbl.pdf", "coaStatus": "verified", "provenance": 100, "quality": 76, "provenanceN": 40, "qualityN": 320, "notes": "Oral semaglutide; requires dosing on empty stomach with limited water.", "makerSlug": "novo-nordisk", "accentColor": "#0A4DA0" }, { "slug": "mounjaro", "name": "Mounjaro", "brandName": "Mounjaro", "manufacturer": "Eli Lilly", "vendor": "Eli Lilly", "substanceSlugs": [ "tirzepatide" ], "strengthMg": 15, "strengthUnit": "mg", "packSize": "Pre-filled pen, 4 doses", "doseLabel": "2.5 / 5 / 7.5 / 10 / 12.5 / 15 mg pen", "jurisdiction": "US / EU / UK", "category": "medicine", "regulatoryStatus": "FDA-approved · EMA · MHRA", "approvedFor": [ "Type 2 diabetes" ], "prescriptionOnly": true, "rxUrl": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215866s011lbl.pdf", "coaStatus": "verified", "provenance": 100, "quality": 87, "provenanceN": 45, "qualityN": 740, "notes": "Lilly KwikPen; on-label for T2D.", "imageUrl": "/pens/mounjaro-5.png", "makerSlug": "eli-lilly", "accentColor": "#7A2E2E", "variants": [ { "label": "2.5 mg", "strengthMg": 2.5, "strengthUnit": "mg", "imageUrl": "/pens/mounjaro-2-5.png", "color": "#CFCFCF" }, { "label": "5 mg", "strengthMg": 5, "strengthUnit": "mg", "imageUrl": "/pens/mounjaro-5.png", "color": "#7AB36F" }, { "label": "7.5 mg", "strengthMg": 7.5, "strengthUnit": "mg", "imageUrl": "/pens/mounjaro-7-5.png", "color": "#5BB3E0" }, { "label": "10 mg", "strengthMg": 10, "strengthUnit": "mg", "imageUrl": "/pens/mounjaro-10.png", "color": "#E89A2B" }, { "label": "12.5 mg", "strengthMg": 12.5, "strengthUnit": "mg", "imageUrl": "/pens/mounjaro-kwikpen.png", "color": "#C2185B" }, { "label": "15 mg", "strengthMg": 15, "strengthUnit": "mg", "imageUrl": "/pens/mounjaro-15.png", "color": "#7A2E2E" } ] }, { "slug": "zepbound", "name": "Zepbound", "brandName": "Zepbound", "manufacturer": "Eli Lilly", "vendor": "Eli Lilly", "substanceSlugs": [ "tirzepatide" ], "strengthMg": 15, "strengthUnit": "mg", "packSize": "Pre-filled pen, 4 doses", "doseLabel": "2.5 / 5 / 7.5 / 10 / 12.5 / 15 mg pen", "jurisdiction": "US", "category": "medicine", "regulatoryStatus": "FDA-approved", "approvedFor": [ "Chronic weight management", "Obstructive sleep apnea with obesity" ], "prescriptionOnly": true, "rxUrl": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s002lbl.pdf", "coaStatus": "verified", "provenance": 100, "quality": 88, "provenanceN": 40, "qualityN": 690, "notes": "Same molecule as Mounjaro; on-label for weight management and OSA.", "imageUrl": "/assets/pen-autoinject-BX7VkYMx.jpg", "makerSlug": "eli-lilly", "accentColor": "#1F5F4A", "variants": [ { "label": "2.5 mg", "strengthMg": 2.5, "strengthUnit": "mg", "imageUrl": "/assets/pen-autoinject-BX7VkYMx.jpg", "color": "#CFCFCF" }, { "label": "5 mg", "strengthMg": 5, "strengthUnit": "mg", "imageUrl": "/assets/pen-autoinject-BX7VkYMx.jpg", "color": "#7AB36F" }, { "label": "7.5 mg", "strengthMg": 7.5, "strengthUnit": "mg", "imageUrl": "/assets/pen-autoinject-BX7VkYMx.jpg", "color": "#5BB3E0" }, { "label": "10 mg", "strengthMg": 10, "strengthUnit": "mg", "imageUrl": "/assets/pen-autoinject-BX7VkYMx.jpg", "color": "#E89A2B" }, { "label": "12.5 mg", "strengthMg": 12.5, "strengthUnit": "mg", "imageUrl": "/assets/pen-autoinject-BX7VkYMx.jpg", "color": "#C2185B" }, { "label": "15 mg", "strengthMg": 15, "strengthUnit": "mg", "imageUrl": "/assets/pen-autoinject-BX7VkYMx.jpg", "color": "#1F5F4A" } ] }, { "slug": "saxenda", "name": "Saxenda", "brandName": "Saxenda", "manufacturer": "Novo Nordisk", "vendor": "Novo Nordisk", "substanceSlugs": [ "liraglutide" ], "strengthMg": 3, "strengthUnit": "mg", "packSize": "Multi-dose pen, 5×3 mL", "doseLabel": "0.6–3.0 mg/day pen", "jurisdiction": "US / EU / UK", "category": "medicine", "regulatoryStatus": "FDA-approved · EMA · MHRA", "approvedFor": [ "Chronic weight management" ], "prescriptionOnly": true, "rxUrl": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206321s016lbl.pdf", "coaStatus": "verified", "provenance": 100, "quality": 72, "provenanceN": 40, "qualityN": 410, "notes": "Daily injection; older than semaglutide.", "imageUrl": "/assets/pen-multidose-m6T0YJCF.jpg", "makerSlug": "novo-nordisk", "accentColor": "#0A4DA0", "variants": [ { "label": "0.6 mg", "strengthMg": 0.6, "strengthUnit": "mg", "imageUrl": "/assets/pen-multidose-m6T0YJCF.jpg", "color": "#5BB3E0" }, { "label": "1.2 mg", "strengthMg": 1.2, "strengthUnit": "mg", "imageUrl": "/assets/pen-multidose-m6T0YJCF.jpg", "color": "#3FA85B" }, { "label": "1.8 mg", "strengthMg": 1.8, "strengthUnit": "mg", "imageUrl": "/assets/pen-multidose-m6T0YJCF.jpg", "color": "#E89A2B" }, { "label": "2.4 mg", "strengthMg": 2.4, "strengthUnit": "mg", "imageUrl": "/assets/pen-multidose-m6T0YJCF.jpg", "color": "#C2185B" }, { "label": "3.0 mg", "strengthMg": 3, "strengthUnit": "mg", "imageUrl": "/assets/pen-multidose-m6T0YJCF.jpg", "color": "#0A4DA0" } ] }, { "slug": "victoza", "name": "Victoza", "brandName": "Victoza", "manufacturer": "Novo Nordisk", "vendor": "Novo Nordisk", "substanceSlugs": [ "liraglutide" ], "strengthMg": 1.8, "strengthUnit": "mg", "packSize": "Multi-dose pen, 2×3 mL", "doseLabel": "0.6 / 1.2 / 1.8 mg/day pen", "jurisdiction": "US / EU / UK", "category": "medicine", "regulatoryStatus": "FDA-approved · EMA · MHRA", "approvedFor": [ "Type 2 diabetes" ], "prescriptionOnly": true, "rxUrl": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022341s035lbl.pdf", "coaStatus": "verified", "provenance": 100, "quality": 70, "provenanceN": 40, "qualityN": 380, "notes": "Same molecule as Saxenda; on-label for T2D.", "imageUrl": "/assets/pen-multidose-m6T0YJCF.jpg", "makerSlug": "novo-nordisk", "accentColor": "#0A4DA0", "variants": [ { "label": "0.6 mg", "strengthMg": 0.6, "strengthUnit": "mg", "imageUrl": "/assets/pen-multidose-m6T0YJCF.jpg", "color": "#5BB3E0" }, { "label": "1.2 mg", "strengthMg": 1.2, "strengthUnit": "mg", "imageUrl": "/assets/pen-multidose-m6T0YJCF.jpg", "color": "#3FA85B" }, { "label": "1.8 mg", "strengthMg": 1.8, "strengthUnit": "mg", "imageUrl": "/assets/pen-multidose-m6T0YJCF.jpg", "color": "#0A4DA0" } ] }, { "slug": "trulicity", "name": "Trulicity", "brandName": "Trulicity", "manufacturer": "Eli Lilly", "vendor": "Eli Lilly", "substanceSlugs": [ "dulaglutide" ], "strengthMg": 4.5, "strengthUnit": "mg", "packSize": "Pre-filled pen, single use", "doseLabel": "0.75 / 1.5 / 3.0 / 4.5 mg/week pen", "jurisdiction": "US / EU / UK", "category": "medicine", "regulatoryStatus": "FDA-approved · EMA · MHRA", "approvedFor": [ "Type 2 diabetes", "Cardiovascular risk reduction" ], "prescriptionOnly": true, "rxUrl": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125469s041lbl.pdf", "coaStatus": "verified", "provenance": 100, "quality": 78, "provenanceN": 35, "qualityN": 290, "notes": "Auto-injector; weekly.", "imageUrl": "/assets/pen-autoinject-BX7VkYMx.jpg", "makerSlug": "eli-lilly", "accentColor": "#1B5FA0", "variants": [ { "label": "0.75 mg", "strengthMg": 0.75, "strengthUnit": "mg", "imageUrl": "/assets/pen-autoinject-BX7VkYMx.jpg", "color": "#5BB3E0" }, { "label": "1.5 mg", "strengthMg": 1.5, "strengthUnit": "mg", "imageUrl": "/assets/pen-autoinject-BX7VkYMx.jpg", "color": "#1B5FA0" }, { "label": "3.0 mg", "strengthMg": 3, "strengthUnit": "mg", "imageUrl": "/assets/pen-autoinject-BX7VkYMx.jpg", "color": "#E89A2B" }, { "label": "4.5 mg", "strengthMg": 4.5, "strengthUnit": "mg", "imageUrl": "/assets/pen-autoinject-BX7VkYMx.jpg", "color": "#C2185B" } ] }, { "slug": "byetta", "name": "Byetta", "brandName": "Byetta", "manufacturer": "AstraZeneca", "vendor": "AstraZeneca", "substanceSlugs": [ "exenatide" ], "strengthMg": 0.01, "strengthUnit": "mg", "packSize": "Multi-dose pen", "doseLabel": "5 / 10 mcg BID pen", "jurisdiction": "US / EU", "category": "medicine", "regulatoryStatus": "FDA-approved · EMA", "approvedFor": [ "Type 2 diabetes" ], "prescriptionOnly": true, "rxUrl": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021773s054lbl.pdf", "coaStatus": "verified", "provenance": 100, "quality": 64, "provenanceN": 30, "qualityN": 210, "notes": "BID immediate-release form.", "makerSlug": "astrazeneca", "accentColor": "#7A1B1B" }, { "slug": "bydureon-bcise", "name": "Bydureon BCise", "brandName": "Bydureon BCise", "manufacturer": "AstraZeneca", "vendor": "AstraZeneca", "substanceSlugs": [ "exenatide" ], "strengthMg": 2, "strengthUnit": "mg", "packSize": "Single-dose autoinjector", "doseLabel": "2 mg/week autoinjector", "jurisdiction": "US / EU", "category": "medicine", "regulatoryStatus": "FDA-approved · EMA", "approvedFor": [ "Type 2 diabetes" ], "prescriptionOnly": true, "rxUrl": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209210s000lbl.pdf", "coaStatus": "verified", "provenance": 100, "quality": 65, "provenanceN": 25, "qualityN": 180, "notes": "Weekly extended-release form." }, { "slug": "egrifta-sv", "name": "Egrifta SV", "brandName": "Egrifta SV", "manufacturer": "Theratechnologies", "vendor": "Theratechnologies", "substanceSlugs": [ "tesamorelin" ], "strengthMg": 2, "strengthUnit": "mg", "packSize": "Single-dose vial", "doseLabel": "2 mg/day vial", "jurisdiction": "US", "category": "medicine", "regulatoryStatus": "FDA-approved", "approvedFor": [ "HIV-associated lipodystrophy" ], "prescriptionOnly": true, "rxUrl": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213005s000lbl.pdf", "coaStatus": "verified", "provenance": 100, "quality": 70, "provenanceN": 20, "qualityN": 95, "notes": "On-label for HIV lipodystrophy." }, { "slug": "vyleesi", "name": "Vyleesi", "brandName": "Vyleesi", "manufacturer": "Cosette Pharmaceuticals", "vendor": "Cosette Pharmaceuticals", "substanceSlugs": [ "pt-141" ], "strengthMg": 1.75, "strengthUnit": "mg", "packSize": "Single-use autoinjector", "doseLabel": "1.75 mg/0.3 mL on-demand", "jurisdiction": "US", "category": "medicine", "regulatoryStatus": "FDA-approved", "approvedFor": [ "Hypoactive sexual desire disorder (premenopausal women)" ], "prescriptionOnly": true, "rxUrl": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf", "coaStatus": "verified", "provenance": 100, "quality": 62, "provenanceN": 18, "qualityN": 130, "notes": "On-demand autoinjector." }, { "slug": "imcivree", "name": "Imcivree", "brandName": "Imcivree", "manufacturer": "Rhythm Pharmaceuticals", "vendor": "Rhythm Pharmaceuticals", "substanceSlugs": [ "setmelanotide" ], "strengthMg": 10, "strengthUnit": "mg/mL", "packSize": "Multi-dose vial 10 mg/mL", "doseLabel": "2–3 mg/day SC", "jurisdiction": "US / EU", "category": "medicine", "regulatoryStatus": "FDA-approved · EMA", "approvedFor": [ "POMC / PCSK1 / LEPR / BBS obesity" ], "prescriptionOnly": true, "rxUrl": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213793s006lbl.pdf", "coaStatus": "verified", "provenance": 100, "quality": 70, "provenanceN": 10, "qualityN": 60, "notes": "Specialty drug; narrow indication." }, { "slug": "scenesse", "name": "Scenesse", "brandName": "Scenesse", "manufacturer": "Clinuvel", "vendor": "Clinuvel", "substanceSlugs": [ "melanotan-1" ], "strengthMg": 16, "strengthUnit": "mg", "packSize": "Single SC implant", "doseLabel": "16 mg implant every 2 months", "jurisdiction": "US / EU", "category": "medicine", "regulatoryStatus": "FDA-approved · EMA", "approvedFor": [ "Erythropoietic protoporphyria" ], "prescriptionOnly": true, "rxUrl": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf", "coaStatus": "verified", "provenance": 100, "quality": 75, "provenanceN": 8, "qualityN": 50, "notes": "Subcutaneous implant administered by clinician." }, { "slug": "cerebrolysin-ever", "name": "Cerebrolysin", "brandName": "Cerebrolysin", "manufacturer": "EVER Pharma", "vendor": "EVER Pharma", "substanceSlugs": [ "cerebrolysin" ], "strengthMg": 215.2, "strengthUnit": "mg/mL", "packSize": "5 / 10 mL ampoule", "doseLabel": "5–30 mL/day IV", "jurisdiction": "EU / Asia (not US)", "category": "medicine", "regulatoryStatus": "Approved (AT, DE, RU, CN, others)", "approvedFor": [ "Stroke", "Dementia (varies by jurisdiction)" ], "prescriptionOnly": true, "rxUrl": "https://www.everpharma.com/en/cerebrolysin", "coaStatus": "verified", "provenance": 95, "quality": 60, "provenanceN": 15, "qualityN": 220, "notes": "Approved in Europe/Asia; not approved in US." }, { "slug": "increlex", "name": "Increlex", "brandName": "Increlex", "manufacturer": "Ipsen", "vendor": "Ipsen", "substanceSlugs": [ "mecasermin" ], "strengthMg": 10, "strengthUnit": "mg/mL", "packSize": "4 mL vial", "doseLabel": "0.04–0.12 mg/kg BID", "jurisdiction": "US / EU", "category": "medicine", "regulatoryStatus": "FDA-approved · EMA", "approvedFor": [ "Severe primary IGF-1 deficiency" ], "prescriptionOnly": true, "rxUrl": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021839s003lbl.pdf", "coaStatus": "verified", "provenance": 100, "quality": 70, "provenanceN": 10, "qualityN": 40, "notes": "Specialty paediatric Rx." }, { "slug": "zadaxin", "name": "Zadaxin", "brandName": "Zadaxin", "manufacturer": "SciClone Pharmaceuticals", "vendor": "SciClone Pharmaceuticals", "substanceSlugs": [ "thymosin-alpha-1" ], "strengthMg": 1.6, "strengthUnit": "mg", "packSize": "Single-dose vial", "doseLabel": "1.6 mg, 2× weekly", "jurisdiction": "EU / Asia / LatAm (not US)", "category": "medicine", "regulatoryStatus": "Approved in 30+ countries (not US)", "approvedFor": [ "Chronic hepatitis B", "Chronic hepatitis C (adjunct)" ], "prescriptionOnly": true, "rxUrl": "https://www.sciclone.com/zadaxin", "coaStatus": "verified", "provenance": 95, "quality": 62, "provenanceN": 12, "qualityN": 80, "notes": "Not approved in US; common in EU/Asia." }, { "slug": "pregnyl", "name": "Pregnyl", "brandName": "Pregnyl", "manufacturer": "Organon", "vendor": "Organon", "substanceSlugs": [ "hcg" ], "strengthMg": 0.1, "strengthUnit": "IU", "packSize": "1500–10000 IU vial", "doseLabel": "500–10000 IU per protocol", "jurisdiction": "US / EU / UK", "category": "medicine", "regulatoryStatus": "FDA-approved · EMA · MHRA", "approvedFor": [ "Ovulation induction", "Male hypogonadism", "Cryptorchidism" ], "prescriptionOnly": true, "rxUrl": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/017016s033lbl.pdf", "coaStatus": "verified", "provenance": 100, "quality": 70, "provenanceN": 20, "qualityN": 110, "notes": "Urinary-derived hCG." }, { "slug": "ovidrel", "name": "Ovidrel", "brandName": "Ovidrel", "manufacturer": "Merck Serono", "vendor": "Merck Serono", "substanceSlugs": [ "hcg" ], "strengthMg": 0.25, "strengthUnit": "mg", "packSize": "Pre-filled syringe", "doseLabel": "250 mcg (≈6500 IU) single dose", "jurisdiction": "US / EU / UK", "category": "medicine", "regulatoryStatus": "FDA-approved · EMA · MHRA", "approvedFor": [ "Ovulation induction" ], "prescriptionOnly": true, "rxUrl": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021149s016lbl.pdf", "coaStatus": "verified", "provenance": 100, "quality": 72, "provenanceN": 15, "qualityN": 80, "notes": "Recombinant hCG." }, { "slug": "geref", "name": "Geref", "brandName": "Geref", "manufacturer": "EMD Serono (legacy)", "vendor": "EMD Serono", "substanceSlugs": [ "sermorelin" ], "strengthMg": 0.5, "strengthUnit": "mg", "packSize": "Single-dose vial", "doseLabel": "0.03 mg/kg/day SC", "jurisdiction": "US (discontinued 2008)", "category": "medicine", "regulatoryStatus": "FDA-approved (discontinued)", "approvedFor": [ "Paediatric growth hormone deficiency" ], "prescriptionOnly": true, "rxUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019863", "coaStatus": "verified", "provenance": 95, "quality": 55, "provenanceN": 8, "qualityN": 25, "notes": "Commercially discontinued; reference only." }, { "slug": "pitocin", "name": "Pitocin", "brandName": "Pitocin", "manufacturer": "JHP Pharmaceuticals", "vendor": "JHP Pharmaceuticals", "substanceSlugs": [ "oxytocin" ], "strengthMg": 0.01, "strengthUnit": "IU", "packSize": "10 IU/mL vial", "doseLabel": "Labour induction IV", "jurisdiction": "US", "category": "medicine", "regulatoryStatus": "FDA-approved", "approvedFor": [ "Labour induction", "Postpartum haemorrhage" ], "prescriptionOnly": true, "rxUrl": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/018261s031lbl.pdf", "coaStatus": "verified", "provenance": 100, "quality": 75, "provenanceN": 30, "qualityN": 200, "notes": "Hospital-administered only." }, { "slug": "hallandale-semaglutide-2mg-ml", "name": "Compounded Semaglutide 2 mg/mL", "brandName": "Hallandale Semaglutide", "manufacturer": "Hallandale Pharmacy", "vendor": "Hallandale Pharmacy", "substanceSlugs": [ "semaglutide" ], "strengthMg": 2, "strengthUnit": "mg/mL", "packSize": "5 mL vial", "doseLabel": "2 mg/mL, 5 mL vial", "jurisdiction": "US — 503A", "category": "compounded", "regulatoryStatus": "503A", "approvedFor": [], "prescriptionOnly": true, "rxUrl": "", "coaStatus": "verified", "provenance": 82, "quality": 76, "provenanceN": 22, "qualityN": 156, "notes": "Pharmacist-attested potency; commonly paired with B12 or B6." }, { "slug": "empower-semaglutide-2-5mg-ml", "name": "Compounded Semaglutide 2.5 mg/mL", "brandName": "Empower Semaglutide", "manufacturer": "Empower Pharmacy", "vendor": "Empower Pharmacy", "substanceSlugs": [ "semaglutide" ], "strengthMg": 2.5, "strengthUnit": "mg/mL", "packSize": "4 mL vial", "doseLabel": "2.5 mg/mL, 4 mL vial", "jurisdiction": "US — 503A", "category": "compounded", "regulatoryStatus": "503A", "approvedFor": [], "prescriptionOnly": true, "rxUrl": "", "coaStatus": "verified", "provenance": 84, "quality": 77, "provenanceN": 25, "qualityN": 180, "notes": "Empower also operates a 503B outsourcing facility; verify which licence ships your order." }, { "slug": "olympia-semaglutide-2mg-ml", "name": "Compounded Semaglutide 2 mg/mL", "brandName": "Olympia Semaglutide", "manufacturer": "Olympia Pharmacy", "vendor": "Olympia Pharmacy", "substanceSlugs": [ "semaglutide" ], "strengthMg": 2, "strengthUnit": "mg/mL", "packSize": "2.5 mL vial", "doseLabel": "2 mg/mL, 2.5 mL vial", "jurisdiction": "US — 503A", "category": "compounded", "regulatoryStatus": "503A", "approvedFor": [], "prescriptionOnly": true, "rxUrl": "", "coaStatus": "verified", "provenance": 78, "quality": 73, "provenanceN": 18, "qualityN": 132, "notes": "Direct-to-clinician compounded semaglutide." }, { "slug": "belmarrx-semaglutide", "name": "Compounded Semaglutide", "brandName": "BelmarRx Semaglutide", "manufacturer": "BelmarRx", "vendor": "BelmarRx", "substanceSlugs": [ "semaglutide" ], "strengthMg": 2, "strengthUnit": "mg/mL", "packSize": "5 mL vial", "doseLabel": "2 mg/mL, 5 mL vial", "jurisdiction": "US — 503A", "category": "compounded", "regulatoryStatus": "503A", "approvedFor": [], "prescriptionOnly": true, "rxUrl": "", "coaStatus": "claimed", "provenance": 70, "quality": 68, "provenanceN": 12, "qualityN": 90, "notes": "Smaller-volume compounder; longer turnaround." }, { "slug": "empower-tirzepatide-10mg-ml", "name": "Compounded Tirzepatide 10 mg/mL", "brandName": "Empower Tirzepatide", "manufacturer": "Empower Pharmacy", "vendor": "Empower Pharmacy", "substanceSlugs": [ "tirzepatide" ], "strengthMg": 10, "strengthUnit": "mg/mL", "packSize": "2 mL vial", "doseLabel": "10 mg/mL, 2 mL vial", "jurisdiction": "US — 503A", "category": "compounded", "regulatoryStatus": "503A", "approvedFor": [], "prescriptionOnly": true, "rxUrl": "", "coaStatus": "verified", "provenance": 80, "quality": 74, "provenanceN": 20, "qualityN": 145, "notes": "FDA removed tirzepatide from shortage in 2024 — verify pharmacy is still compounding lawfully." }, { "slug": "hallandale-tirzepatide", "name": "Compounded Tirzepatide", "brandName": "Hallandale Tirzepatide", "manufacturer": "Hallandale Pharmacy", "vendor": "Hallandale Pharmacy", "substanceSlugs": [ "tirzepatide" ], "strengthMg": 10, "strengthUnit": "mg/mL", "packSize": "2 mL vial", "doseLabel": "10 mg/mL, 2 mL vial", "jurisdiction": "US — 503A", "category": "compounded", "regulatoryStatus": "503A", "approvedFor": [], "prescriptionOnly": true, "rxUrl": "", "coaStatus": "verified", "provenance": 78, "quality": 72, "provenanceN": 16, "qualityN": 110, "notes": "Shortage status changed in 2024; check current FDA list." }, { "slug": "strive-tirzepatide", "name": "Compounded Tirzepatide", "brandName": "Strive Tirzepatide", "manufacturer": "Strive Pharmacy", "vendor": "Strive Pharmacy", "substanceSlugs": [ "tirzepatide" ], "strengthMg": 10, "strengthUnit": "mg/mL", "packSize": "2 mL vial", "doseLabel": "10 mg/mL, 2 mL vial", "jurisdiction": "US — 503A", "category": "compounded", "regulatoryStatus": "503A", "approvedFor": [], "prescriptionOnly": true, "rxUrl": "", "coaStatus": "claimed", "provenance": 68, "quality": 66, "provenanceN": 10, "qualityN": 65, "notes": "Direct-to-consumer through telehealth networks." }, { "slug": "empower-sermorelin-15mg", "name": "Compounded Sermorelin 15 mg", "brandName": "Empower Sermorelin", "manufacturer": "Empower Pharmacy", "vendor": "Empower Pharmacy", "substanceSlugs": [ "sermorelin" ], "strengthMg": 15, "strengthUnit": "mg", "packSize": "Lyophilised vial", "doseLabel": "15 mg lyophilised vial", "jurisdiction": "US — 503A", "category": "compounded", "regulatoryStatus": "503A", "approvedFor": [], "prescriptionOnly": true, "rxUrl": "", "coaStatus": "verified", "provenance": 82, "quality": 70, "provenanceN": 14, "qualityN": 75, "notes": "Common in US anti-aging clinics." }, { "slug": "tailormade-sermorelin-cjc", "name": "Sermorelin / CJC-1295 blend", "brandName": "Tailor Made Sermorelin+CJC", "manufacturer": "Tailor Made Compounding", "vendor": "Tailor Made Compounding", "substanceSlugs": [ "sermorelin", "cjc-1295-no-dac" ], "strengthMg": 9, "strengthUnit": "mg", "packSize": "Lyophilised vial", "doseLabel": "Sermorelin 3 mg + CJC 6 mg vial", "jurisdiction": "US — 503A", "category": "compounded", "regulatoryStatus": "503A", "approvedFor": [], "prescriptionOnly": true, "rxUrl": "", "coaStatus": "claimed", "provenance": 70, "quality": 65, "provenanceN": 9, "qualityN": 55, "notes": "Combo product; clinical evidence for combination is thin." }, { "slug": "empower-tesamorelin-10mg", "name": "Compounded Tesamorelin 10 mg", "brandName": "Empower Tesamorelin", "manufacturer": "Empower Pharmacy", "vendor": "Empower Pharmacy", "substanceSlugs": [ "tesamorelin" ], "strengthMg": 10, "strengthUnit": "mg", "packSize": "Lyophilised vial", "doseLabel": "10 mg lyophilised vial", "jurisdiction": "US — 503A", "category": "compounded", "regulatoryStatus": "503A", "approvedFor": [], "prescriptionOnly": true, "rxUrl": "", "coaStatus": "verified", "provenance": 80, "quality": 68, "provenanceN": 10, "qualityN": 45, "notes": "Off-label use outside HIV indication." }, { "slug": "empower-bpc-157-legacy", "name": "BPC-157 5 mg (compounded, legacy)", "brandName": "Empower BPC-157", "manufacturer": "Empower Pharmacy", "vendor": "Empower Pharmacy", "substanceSlugs": [ "bpc-157" ], "strengthMg": 5, "strengthUnit": "mg", "packSize": "Lyophilised vial", "doseLabel": "5 mg lyophilised vial", "jurisdiction": "US — 503A (historical)", "category": "compounded", "regulatoryStatus": "503A (FDA flagged 2023)", "approvedFor": [], "prescriptionOnly": true, "rxUrl": "", "coaStatus": "verified", "provenance": 72, "quality": 70, "provenanceN": 14, "qualityN": 92, "notes": "FDA placed BPC-157 on Category 2 of the 503A bulks list in 2023, restricting compounding. Historical reference." }, { "slug": "empower-ipamorelin-10mg", "name": "Compounded Ipamorelin 10 mg", "brandName": "Empower Ipamorelin", "manufacturer": "Empower Pharmacy", "vendor": "Empower Pharmacy", "substanceSlugs": [ "ipamorelin" ], "strengthMg": 10, "strengthUnit": "mg", "packSize": "Lyophilised vial", "doseLabel": "10 mg lyophilised vial", "jurisdiction": "US — 503A (historical)", "category": "compounded", "regulatoryStatus": "503A (FDA flagged 2023)", "approvedFor": [], "prescriptionOnly": true, "rxUrl": "", "coaStatus": "verified", "provenance": 75, "quality": 68, "provenanceN": 11, "qualityN": 47, "notes": "Ipamorelin was placed on Category 2 of the 503A bulks list in 2023." }, { "slug": "revive-pt-141-10mg", "name": "Compounded PT-141 10 mg", "brandName": "Revive Rx PT-141", "manufacturer": "Revive Rx", "vendor": "Revive Rx", "substanceSlugs": [ "pt-141" ], "strengthMg": 10, "strengthUnit": "mg", "packSize": "Lyophilised vial", "doseLabel": "10 mg vial", "jurisdiction": "US — 503A", "category": "compounded", "regulatoryStatus": "503A", "approvedFor": [], "prescriptionOnly": true, "rxUrl": "", "coaStatus": "claimed", "provenance": 68, "quality": 60, "provenanceN": 8, "qualityN": 38, "notes": "Sold via telehealth networks; verify pharmacy licence." }, { "slug": "empower-oxytocin-nasal", "name": "Compounded Oxytocin nasal", "brandName": "Empower Oxytocin Nasal", "manufacturer": "Empower Pharmacy", "vendor": "Empower Pharmacy", "substanceSlugs": [ "oxytocin" ], "strengthMg": 0.04, "strengthUnit": "IU/spray", "packSize": "Nasal spray 10 mL", "doseLabel": "40 IU/mL nasal spray", "jurisdiction": "US — 503A", "category": "compounded", "regulatoryStatus": "503A", "approvedFor": [], "prescriptionOnly": true, "rxUrl": "", "coaStatus": "verified", "provenance": 75, "quality": 62, "provenanceN": 10, "qualityN": 55, "notes": "Off-label nasal preparation." }, { "slug": "peptide-sciences-bpc-157-5mg", "name": "BPC-157 5 mg vial", "brandName": "Peptide Sciences BPC-157", "manufacturer": "Peptide Sciences", "vendor": "Peptide Sciences", "substanceSlugs": [ "bpc-157" ], "strengthMg": 5, "strengthUnit": "mg", "packSize": "Lyophilised vial", "doseLabel": "5 mg lyophilised", "jurisdiction": "US — RUO", "category": "research", "regulatoryStatus": "RUO", "approvedFor": [], "prescriptionOnly": false, "rxUrl": "", "coaStatus": "verified", "provenance": 78, "quality": 71, "provenanceN": 14, "qualityN": 92, "notes": "Third-party HPLC published per batch. For laboratory research only." }, { "slug": "peptide-sciences-ipamorelin-5mg", "name": "Ipamorelin 5 mg vial", "brandName": "Peptide Sciences Ipamorelin", "manufacturer": "Peptide Sciences", "vendor": "Peptide Sciences", "substanceSlugs": [ "ipamorelin" ], "strengthMg": 5, "strengthUnit": "mg", "packSize": "Lyophilised vial", "doseLabel": "5 mg lyophilised", "jurisdiction": "US — RUO", "category": "research", "regulatoryStatus": "RUO", "approvedFor": [], "prescriptionOnly": false, "rxUrl": "", "coaStatus": "verified", "provenance": 74, "quality": 68, "provenanceN": 11, "qualityN": 47, "notes": "Consistent third-party potency reports across last 8 batches." }, { "slug": "peptide-sciences-tb-500-5mg", "name": "TB-500 5 mg vial", "brandName": "Peptide Sciences TB-500", "manufacturer": "Peptide Sciences", "vendor": "Peptide Sciences", "substanceSlugs": [ "tb-500" ], "strengthMg": 5, "strengthUnit": "mg", "packSize": "Lyophilised vial", "doseLabel": "5 mg lyophilised", "jurisdiction": "US — RUO", "category": "research", "regulatoryStatus": "RUO", "approvedFor": [], "prescriptionOnly": false, "rxUrl": "", "coaStatus": "verified", "provenance": 76, "quality": 65, "provenanceN": 12, "qualityN": 60, "notes": "Published HPLC reports per lot." }, { "slug": "peptide-sciences-semaglutide-5mg", "name": "Semaglutide 5 mg vial", "brandName": "Peptide Sciences Semaglutide", "manufacturer": "Peptide Sciences", "vendor": "Peptide Sciences", "substanceSlugs": [ "semaglutide" ], "strengthMg": 5, "strengthUnit": "mg", "packSize": "Lyophilised vial", "doseLabel": "5 mg lyophilised", "jurisdiction": "US — RUO", "category": "research", "regulatoryStatus": "RUO", "approvedFor": [], "prescriptionOnly": false, "rxUrl": "", "coaStatus": "verified", "provenance": 70, "quality": 60, "provenanceN": 10, "qualityN": 55, "notes": "Reconstitution required. For laboratory research only." }, { "slug": "peptide-sciences-tirzepatide-10mg", "name": "Tirzepatide 10 mg vial", "brandName": "Peptide Sciences Tirzepatide", "manufacturer": "Peptide Sciences", "vendor": "Peptide Sciences", "substanceSlugs": [ "tirzepatide" ], "strengthMg": 10, "strengthUnit": "mg", "packSize": "Lyophilised vial", "doseLabel": "10 mg lyophilised", "jurisdiction": "US — RUO", "category": "research", "regulatoryStatus": "RUO", "approvedFor": [], "prescriptionOnly": false, "rxUrl": "", "coaStatus": "verified", "provenance": 70, "quality": 62, "provenanceN": 8, "qualityN": 38, "notes": "For laboratory research only." }, { "slug": "peptide-sciences-cjc-dac-5mg", "name": "CJC-1295 DAC 5 mg vial", "brandName": "Peptide Sciences CJC-1295 DAC", "manufacturer": "Peptide Sciences", "vendor": "Peptide Sciences", "substanceSlugs": [ "cjc-1295-dac" ], "strengthMg": 5, "strengthUnit": "mg", "packSize": "Lyophilised vial", "doseLabel": "5 mg lyophilised", "jurisdiction": "US — RUO", "category": "research", "regulatoryStatus": "RUO", "approvedFor": [], "prescriptionOnly": false, "rxUrl": "", "coaStatus": "verified", "provenance": 72, "quality": 64, "provenanceN": 9, "qualityN": 42, "notes": "Long-acting GHRH analogue." }, { "slug": "peptide-sciences-ghk-cu-50mg", "name": "GHK-Cu 50 mg vial", "brandName": "Peptide Sciences GHK-Cu", "manufacturer": "Peptide Sciences", "vendor": "Peptide Sciences", "substanceSlugs": [ "ghk-cu" ], "strengthMg": 50, "strengthUnit": "mg", "packSize": "Lyophilised vial", "doseLabel": "50 mg lyophilised", "jurisdiction": "US — RUO", "category": "research", "regulatoryStatus": "RUO", "approvedFor": [], "prescriptionOnly": false, "rxUrl": "", "coaStatus": "verified", "provenance": 74, "quality": 66, "provenanceN": 10, "qualityN": 38, "notes": "Copper peptide." }, { "slug": "peptide-sciences-pt-141-10mg", "name": "PT-141 10 mg vial", "brandName": "Peptide Sciences PT-141", "manufacturer": "Peptide Sciences", "vendor": "Peptide Sciences", "substanceSlugs": [ "pt-141" ], "strengthMg": 10, "strengthUnit": "mg", "packSize": "Lyophilised vial", "doseLabel": "10 mg lyophilised", "jurisdiction": "US — RUO", "category": "research", "regulatoryStatus": "RUO", "approvedFor": [], "prescriptionOnly": false, "rxUrl": "", "coaStatus": "verified", "provenance": 70, "quality": 60, "provenanceN": 8, "qualityN": 30, "notes": "Bremelanotide. Research only." }, { "slug": "core-peptides-tb-500-5mg", "name": "TB-500 5 mg vial", "brandName": "Core Peptides TB-500", "manufacturer": "Core Peptides", "vendor": "Core Peptides", "substanceSlugs": [ "tb-500" ], "strengthMg": 5, "strengthUnit": "mg", "packSize": "Lyophilised vial", "doseLabel": "5 mg lyophilised", "jurisdiction": "US — RUO", "category": "research", "regulatoryStatus": "RUO", "approvedFor": [], "prescriptionOnly": false, "rxUrl": "", "coaStatus": "claimed", "provenance": 52, "quality": 64, "provenanceN": 8, "qualityN": 41, "notes": "COA claimed but not independently posted. Two batch disputes resolved 2025." }, { "slug": "core-peptides-bpc-157-5mg", "name": "BPC-157 5 mg vial", "brandName": "Core Peptides BPC-157", "manufacturer": "Core Peptides", "vendor": "Core Peptides", "substanceSlugs": [ "bpc-157" ], "strengthMg": 5, "strengthUnit": "mg", "packSize": "Lyophilised vial", "doseLabel": "5 mg lyophilised", "jurisdiction": "US — RUO", "category": "research", "regulatoryStatus": "RUO", "approvedFor": [], "prescriptionOnly": false, "rxUrl": "", "coaStatus": "claimed", "provenance": 55, "quality": 62, "provenanceN": 9, "qualityN": 48, "notes": "COA on request." }, { "slug": "core-peptides-semaglutide-3mg", "name": "Semaglutide 3 mg vial", "brandName": "Core Peptides Semaglutide", "manufacturer": "Core Peptides", "vendor": "Core Peptides", "substanceSlugs": [ "semaglutide" ], "strengthMg": 3, "strengthUnit": "mg", "packSize": "Lyophilised vial", "doseLabel": "3 mg lyophilised", "jurisdiction": "US — RUO", "category": "research", "regulatoryStatus": "RUO", "approvedFor": [], "prescriptionOnly": false, "rxUrl": "", "coaStatus": "claimed", "provenance": 50, "quality": 55, "provenanceN": 6, "qualityN": 28, "notes": "Research-grade." }, { "slug": "pure-rawz-bpc-157-10mg", "name": "BPC-157 10 mg vial", "brandName": "Pure Rawz BPC-157", "manufacturer": "Pure Rawz", "vendor": "Pure Rawz", "substanceSlugs": [ "bpc-157" ], "strengthMg": 10, "strengthUnit": "mg", "packSize": "Lyophilised vial", "doseLabel": "10 mg lyophilised", "jurisdiction": "US — RUO", "category": "research", "regulatoryStatus": "RUO", "approvedFor": [], "prescriptionOnly": false, "rxUrl": "", "coaStatus": "claimed", "provenance": 48, "quality": 56, "provenanceN": 7, "qualityN": 34, "notes": "Bulk research supply." }, { "slug": "pure-rawz-mk-677", "name": "MK-677 (Ibutamoren) solution", "brandName": "Pure Rawz MK-677", "manufacturer": "Pure Rawz", "vendor": "Pure Rawz", "substanceSlugs": [ "mk-677" ], "strengthMg": 25, "strengthUnit": "mg/mL", "packSize": "30 mL solution", "doseLabel": "25 mg/mL liquid", "jurisdiction": "US — RUO", "category": "research", "regulatoryStatus": "RUO", "approvedFor": [], "prescriptionOnly": false, "rxUrl": "", "coaStatus": "claimed", "provenance": 45, "quality": 60, "provenanceN": 6, "qualityN": 60, "notes": "Liquid oral solution." }, { "slug": "limitless-life-bpc-157", "name": "BPC-157 5 mg", "brandName": "Limitless Life BPC-157", "manufacturer": "Limitless Life", "vendor": "Limitless Life", "substanceSlugs": [ "bpc-157" ], "strengthMg": 5, "strengthUnit": "mg", "packSize": "Lyophilised vial", "doseLabel": "5 mg lyophilised", "jurisdiction": "US — RUO", "category": "research", "regulatoryStatus": "RUO", "approvedFor": [], "prescriptionOnly": false, "rxUrl": "", "coaStatus": "verified", "provenance": 72, "quality": 68, "provenanceN": 10, "qualityN": 55, "notes": "Independent COA per batch." }, { "slug": "limitless-life-tirzepatide-30mg", "name": "Tirzepatide 30 mg vial", "brandName": "Limitless Life Tirzepatide", "manufacturer": "Limitless Life", "vendor": "Limitless Life", "substanceSlugs": [ "tirzepatide" ], "strengthMg": 30, "strengthUnit": "mg", "packSize": "Lyophilised vial", "doseLabel": "30 mg lyophilised", "jurisdiction": "US — RUO", "category": "research", "regulatoryStatus": "RUO", "approvedFor": [], "prescriptionOnly": false, "rxUrl": "", "coaStatus": "verified", "provenance": 70, "quality": 66, "provenanceN": 9, "qualityN": 48, "notes": "Bulk research vial." }, { "slug": "limitless-life-retatrutide-10mg", "name": "Retatrutide 10 mg vial", "brandName": "Limitless Life Retatrutide", "manufacturer": "Limitless Life", "vendor": "Limitless Life", "substanceSlugs": [ "retatrutide" ], "strengthMg": 10, "strengthUnit": "mg", "packSize": "Lyophilised vial", "doseLabel": "10 mg lyophilised", "jurisdiction": "US — RUO", "category": "research", "regulatoryStatus": "RUO", "approvedFor": [], "prescriptionOnly": false, "rxUrl": "", "coaStatus": "claimed", "provenance": 58, "quality": 50, "provenanceN": 5, "qualityN": 18, "notes": "Investigational compound; no approved use in humans." }, { "slug": "amino-asylum-melanotan-2", "name": "Melanotan II 10 mg", "brandName": "Amino Asylum MT-II", "manufacturer": "Amino Asylum", "vendor": "Amino Asylum", "substanceSlugs": [ "melanotan-2" ], "strengthMg": 10, "strengthUnit": "mg", "packSize": "Lyophilised vial", "doseLabel": "10 mg lyophilised", "jurisdiction": "US — RUO", "category": "research", "regulatoryStatus": "RUO", "approvedFor": [], "prescriptionOnly": false, "rxUrl": "", "coaStatus": "claimed", "provenance": 40, "quality": 55, "provenanceN": 6, "qualityN": 80, "notes": "MT-II — unapproved, significant adverse-event profile." }, { "slug": "amino-asylum-selank", "name": "Selank 5 mg", "brandName": "Amino Asylum Selank", "manufacturer": "Amino Asylum", "vendor": "Amino Asylum", "substanceSlugs": [ "selank" ], "strengthMg": 5, "strengthUnit": "mg", "packSize": "Lyophilised vial", "doseLabel": "5 mg lyophilised", "jurisdiction": "US — RUO", "category": "research", "regulatoryStatus": "RUO", "approvedFor": [], "prescriptionOnly": false, "rxUrl": "", "coaStatus": "claimed", "provenance": 42, "quality": 58, "provenanceN": 5, "qualityN": 35, "notes": "Research only." }, { "slug": "amino-asylum-semax", "name": "Semax 30 mg", "brandName": "Amino Asylum Semax", "manufacturer": "Amino Asylum", "vendor": "Amino Asylum", "substanceSlugs": [ "semax" ], "strengthMg": 30, "strengthUnit": "mg", "packSize": "Lyophilised vial", "doseLabel": "30 mg lyophilised", "jurisdiction": "US — RUO", "category": "research", "regulatoryStatus": "RUO", "approvedFor": [], "prescriptionOnly": false, "rxUrl": "", "coaStatus": "claimed", "provenance": 42, "quality": 58, "provenanceN": 5, "qualityN": 32, "notes": "Russian-origin nootropic peptide." }, { "slug": "biotech-thymosin-alpha-1-10mg", "name": "Thymosin α1 10 mg vial", "brandName": "BioTech Tα1", "manufacturer": "BioTech Peptides", "vendor": "BioTech Peptides", "substanceSlugs": [ "thymosin-alpha-1" ], "strengthMg": 10, "strengthUnit": "mg", "packSize": "Lyophilised vial", "doseLabel": "10 mg lyophilised", "jurisdiction": "US — RUO", "category": "research", "regulatoryStatus": "RUO", "approvedFor": [], "prescriptionOnly": false, "rxUrl": "", "coaStatus": "verified", "provenance": 68, "quality": 62, "provenanceN": 8, "qualityN": 30, "notes": "Research-grade Tα1." }, { "slug": "biotech-ss-31-50mg", "name": "SS-31 50 mg vial", "brandName": "BioTech SS-31", "manufacturer": "BioTech Peptides", "vendor": "BioTech Peptides", "substanceSlugs": [ "ss-31" ], "strengthMg": 50, "strengthUnit": "mg", "packSize": "Lyophilised vial", "doseLabel": "50 mg lyophilised", "jurisdiction": "US — RUO", "category": "research", "regulatoryStatus": "RUO", "approvedFor": [], "prescriptionOnly": false, "rxUrl": "", "coaStatus": "verified", "provenance": 65, "quality": 58, "provenanceN": 7, "qualityN": 22, "notes": "Elamipretide research supply." }, { "slug": "biotech-epitalon-50mg", "name": "Epitalon 50 mg vial", "brandName": "BioTech Epitalon", "manufacturer": "BioTech Peptides", "vendor": "BioTech Peptides", "substanceSlugs": [ "epitalon" ], "strengthMg": 50, "strengthUnit": "mg", "packSize": "Lyophilised vial", "doseLabel": "50 mg lyophilised", "jurisdiction": "US — RUO", "category": "research", "regulatoryStatus": "RUO", "approvedFor": [], "prescriptionOnly": false, "rxUrl": "", "coaStatus": "verified", "provenance": 64, "quality": 56, "provenanceN": 6, "qualityN": 28, "notes": "AEDG tetrapeptide." }, { "slug": "swiss-chems-bpc-tb-blend", "name": "BPC-157 + TB-500 blend", "brandName": "Swiss Chems BPC+TB Blend", "manufacturer": "Swiss Chems", "vendor": "Swiss Chems", "substanceSlugs": [ "bpc-157", "tb-500" ], "strengthMg": 10, "strengthUnit": "mg", "packSize": "Lyophilised vial", "doseLabel": "BPC 5 mg + TB 5 mg vial", "jurisdiction": "US — RUO", "category": "research", "regulatoryStatus": "RUO", "approvedFor": [], "prescriptionOnly": false, "rxUrl": "", "coaStatus": "claimed", "provenance": 45, "quality": 55, "provenanceN": 6, "qualityN": 38, "notes": "Blended product — clinical evidence for blends is thin." }, { "slug": "swiss-chems-aod-9604", "name": "AOD-9604 5 mg", "brandName": "Swiss Chems AOD-9604", "manufacturer": "Swiss Chems", "vendor": "Swiss Chems", "substanceSlugs": [ "aod-9604" ], "strengthMg": 5, "strengthUnit": "mg", "packSize": "Lyophilised vial", "doseLabel": "5 mg lyophilised", "jurisdiction": "US — RUO", "category": "research", "regulatoryStatus": "RUO", "approvedFor": [], "prescriptionOnly": false, "rxUrl": "", "coaStatus": "claimed", "provenance": 42, "quality": 50, "provenanceN": 5, "qualityN": 25, "notes": "Marketed for weight loss; phase 3 missed endpoints." }, { "slug": "swiss-chems-igf-1-lr3", "name": "IGF-1 LR3 1 mg", "brandName": "Swiss Chems IGF-1 LR3", "manufacturer": "Swiss Chems", "vendor": "Swiss Chems", "substanceSlugs": [ "igf-1-lr3" ], "strengthMg": 1, "strengthUnit": "mg", "packSize": "Lyophilised vial", "doseLabel": "1 mg lyophilised", "jurisdiction": "US — RUO", "category": "research", "regulatoryStatus": "RUO", "approvedFor": [], "prescriptionOnly": false, "rxUrl": "", "coaStatus": "claimed", "provenance": 40, "quality": 52, "provenanceN": 5, "qualityN": 30, "notes": "Long-acting IGF-1 analogue." }, { "slug": "unverified-tirzepatide-vial", "name": "Tirzepatide 10 mg (unverified vendor)", "brandName": "Unlisted Tirzepatide", "manufacturer": "Unlisted", "vendor": "Unlisted", "substanceSlugs": [ "tirzepatide" ], "strengthMg": 10, "strengthUnit": "mg", "packSize": "Lyophilised vial", "doseLabel": "10 mg lyophilised", "jurisdiction": "Grey market", "category": "research", "regulatoryStatus": "Unknown", "approvedFor": [], "prescriptionOnly": false, "rxUrl": "", "coaStatus": "absent", "provenance": 12, "quality": 0, "provenanceN": 3, "qualityN": 0, "notes": "No verifiable COA, no vendor history. Listed for transparency, not endorsement." } ], "conditions": [ { "slug": "tendon-injury", "name": "Tendon & ligament injury", "category": "musculoskeletal", "sensitive": false, "summary": "Soft-tissue recovery is the most commonly reported off-label use of regenerative peptides. Human evidence remains limited.", "reportedSubstances": [ "bpc-157", "tb-500", "thymosin-beta-4" ] }, { "slug": "joint-pain", "name": "Chronic joint pain", "category": "musculoskeletal", "sensitive": false, "summary": "Aggregated cohort reports for joint pain protocols. Read alongside conventional care, not in place of it.", "reportedSubstances": [ "bpc-157", "kpv" ] }, { "slug": "weight-management", "name": "Weight management", "category": "metabolic", "sensitive": false, "summary": "GLP-1 and dual-agonist incretins have the strongest human RCT evidence on this index.", "reportedSubstances": [ "semaglutide", "tirzepatide", "liraglutide", "retatrutide", "tesamorelin", "setmelanotide", "aod-9604" ] }, { "slug": "diabetes", "name": "Diabetes (Type 2)", "category": "metabolic", "sensitive": false, "summary": "Incretin-class agents (GLP-1, dual GIP/GLP-1, triple agonists) and amylin analogues have the strongest human RCT evidence for glycemic control and cardiometabolic risk. Standard care remains first-line; this page is a reference, not a recommendation.", "reportedSubstances": [ "semaglutide", "tirzepatide", "retatrutide", "cagrilintide", "liraglutide" ] }, { "slug": "eating-disorders", "name": "Eating disorders", "category": "sensitive", "sensitive": true, "summary": "If you are in distress, please contact a clinician or local helpline before considering pharmacological options.", "reportedSubstances": [ "semaglutide" ] }, { "slug": "addiction-cravings", "name": "Addiction & cravings", "category": "sensitive", "sensitive": true, "summary": "Emerging observational signal that GLP-1 agonists reduce craving behaviour. Treat as exploratory.", "reportedSubstances": [ "semaglutide" ] }, { "slug": "recovery-sleep", "name": "Recovery & sleep", "category": "recovery", "sensitive": false, "summary": "Reported anecdotally for sleep depth and overnight recovery markers. Largely preclinical mechanism.", "reportedSubstances": [ "ipamorelin", "ghk-cu", "cjc-1295-dac", "sermorelin", "dsip", "epitalon" ] } ], "profiles": [ { "handle": "adachen", "display_name": "Dr. Ada Chen", "tier": "clinician", "created_at": "2026-05-19T07:57:45.550437+00:00" }, { "handle": "marco", "display_name": "Marco Reyes", "tier": "verified", "created_at": "2026-05-19T07:57:45.550437+00:00" }, { "handle": "lena", "display_name": "Lena Ortiz", "tier": "clinician", "created_at": "2026-05-19T07:57:45.550437+00:00" }, { "handle": "fh2210", "display_name": "test fh", "tier": "personal", "created_at": "2026-05-19T11:16:49.917259+00:00" }, { "handle": "joerogan", "display_name": "Joe Rogan", "tier": "personal", "created_at": "2026-05-20T13:37:57.064466+00:00" }, { "handle": "oprah", "display_name": "Oprah Winfrey", "tier": "personal", "created_at": "2026-05-20T13:37:57.064466+00:00" }, { "handle": "khloekardashian", "display_name": "Khloé Kardashian", "tier": "personal", "created_at": "2026-05-20T13:37:57.064466+00:00" }, { "handle": "gwyneth", "display_name": "Gwyneth Paltrow", "tier": "personal", "created_at": "2026-05-20T13:37:57.064466+00:00" }, { "handle": "haileybieber", "display_name": "Hailey Bieber", "tier": "personal", "created_at": "2026-05-20T13:37:57.064466+00:00" }, { "handle": "bryanjohnson", "display_name": "Bryan Johnson", "tier": "personal", "created_at": "2026-05-20T13:37:57.064466+00:00" }, { "handle": "clavicular", "display_name": "Clavicular", "tier": "personal", "created_at": "2026-05-20T13:37:57.064466+00:00" }, { "handle": null, "display_name": "", "tier": "personal", "created_at": "2026-06-13T20:03:57.888245+00:00" }, { "handle": null, "display_name": "", "tier": "personal", "created_at": "2026-07-14T11:08:00.468211+00:00" }, { "handle": null, "display_name": "", "tier": "personal", "created_at": "2026-07-22T09:34:30.390043+00:00" } ], "protocols": [ { "id": "aaaaaaaa-0000-0000-0000-000000000004", "slug": "tirz-metabolic", "name": "Tirzepatide metabolic reset", "tagline": "Dual-agonist for insulin resistance — strict labs cadence.", "stack": [ { "dose": "2.5 mg", "notes": "Baseline + 4-wk fasting insulin.", "route": "subcutaneous", "schedule": "weekly, 4 weeks", "substance_slug": "tirzepatide" } ], "parent_protocol_id": null, "version": 1, "created_at": "2026-05-19T07:57:45.550437+00:00" }, { "id": "aaaaaaaa-0000-0000-0000-000000000003", "slug": "glp1-titrate-mild", "name": "GLP-1 gentle titration", "tagline": "Semaglutide micro-dose ramp to minimize GI side effects.", "stack": [ { "dose": "0.125 mg", "notes": "Stop and reassess if HR>90 resting.", "route": "subcutaneous", "schedule": "weekly for 4 wks, then 0.25 mg", "substance_slug": "semaglutide" } ], "parent_protocol_id": null, "version": 3, "created_at": "2026-05-19T07:57:45.550437+00:00" }, { "id": "aaaaaaaa-0000-0000-0000-000000000001", "slug": "tendon-reset-8wk", "name": "Tendon Reset · 8 weeks", "tagline": "Conservative BPC-157 + TB-500 cycle for partial-thickness tendon injuries.", "stack": [ { "dose": "250 mcg", "notes": "Inject near (not into) the affected tendon.", "route": "subcutaneous", "schedule": "2x daily, 8 weeks", "substance_slug": "bpc-157" }, { "dose": "2 mg", "notes": "Loading dose first 2 weeks.", "route": "subcutaneous", "schedule": "1x weekly, 4 weeks then taper", "substance_slug": "tb-500" } ], "parent_protocol_id": null, "version": 2, "created_at": "2026-05-19T07:57:45.550437+00:00" }, { "id": "e32912ae-ffca-4be5-9f69-da62bcadc356", "slug": "joe-rogan-wolverine", "name": "Wolverine Stack", "tagline": "BPC-157 + TB-500 + GH pulse — recovery & soft-tissue, as discussed on JRE.", "stack": [ { "dose": "250 mcg", "notes": "Injected near affected tissue.", "route": "subcutaneous", "schedule": "2x daily, 4 weeks", "substance_slug": "bpc-157" }, { "dose": "2 mg", "notes": "Loading phase first 2 weeks.", "route": "subcutaneous", "schedule": "1x weekly, 4 weeks", "substance_slug": "tb-500" }, { "dose": "200 mcg", "notes": "Stacked with CJC-1295 for GH pulse.", "route": "subcutaneous", "schedule": "pre-sleep, 5 days/wk", "substance_slug": "ipamorelin" }, { "dose": "100 mcg", "notes": "Paired with ipamorelin.", "route": "subcutaneous", "schedule": "pre-sleep, 5 days/wk", "substance_slug": "cjc-1295-no-dac" } ], "parent_protocol_id": null, "version": 1, "created_at": "2026-05-20T13:34:51.641198+00:00" }, { "id": "aaaaaaaa-0000-0000-0000-000000000002", "slug": "lift-recovery-block", "name": "Heavy-lift recovery block", "tagline": "Post-meet recovery: tissue + sleep stack.", "stack": [ { "dose": "500 mcg", "notes": "", "route": "subcutaneous", "schedule": "daily, 4 weeks", "substance_slug": "bpc-157" }, { "dose": "200 mcg", "notes": "GH pulse for deep sleep.", "route": "subcutaneous", "schedule": "pre-sleep, 4 weeks", "substance_slug": "ipamorelin" } ], "parent_protocol_id": null, "version": 1, "created_at": "2026-05-19T07:57:45.550437+00:00" }, { "id": "35fab289-f8b4-4e3a-92a2-241f6b5da095", "slug": "khloe-semaglutide-curious", "name": "GLP-1 weight-loss starter", "tagline": "Conservative semaglutide protocol — what Khloé has said she \"would have tried\".", "stack": [ { "dose": "0.25 mg", "notes": "Low-and-slow start to limit nausea.", "route": "subcutaneous", "schedule": "weekly, 4 weeks, then titrate", "substance_slug": "semaglutide" } ], "parent_protocol_id": null, "version": 1, "created_at": "2026-05-20T13:34:51.641198+00:00" }, { "id": "4dbfcaa0-b77e-4a9b-b801-14958113363f", "slug": "oprah-glp1-reset", "name": "GLP-1 weight maintenance", "tagline": "Semaglutide protocol Oprah has publicly described using.", "stack": [ { "dose": "0.25 mg → 1.0 mg titration", "notes": "Standard titration over 8+ weeks. Monitor GI tolerance.", "route": "subcutaneous", "schedule": "weekly", "substance_slug": "semaglutide" } ], "parent_protocol_id": null, "version": 1, "created_at": "2026-05-20T13:34:51.641198+00:00" }, { "id": "1559b8bf-cfb7-4ebe-a51c-98752717b6fb", "slug": "gwyneth-microdose-glp1", "name": "Microdose GLP-1", "tagline": "Microdose tirzepatide approach Gwyneth has discussed on Goop.", "stack": [ { "dose": "1.25 mg (microdose)", "notes": "Sub-clinical dose intended for metabolic tuning, not weight loss.", "route": "subcutaneous", "schedule": "weekly", "substance_slug": "tirzepatide" } ], "parent_protocol_id": null, "version": 1, "created_at": "2026-05-20T13:34:51.641198+00:00" }, { "id": "eabecc77-5efa-4b59-9ffc-76fa45cd645d", "slug": "clavicular-general-recovery", "name": "General recovery", "tagline": "Balanced recovery & GH-pulse stack.", "stack": [ { "dose": "500 mcg", "notes": "Systemic repair.", "route": "subcutaneous", "schedule": "daily, 4 weeks", "substance_slug": "bpc-157" }, { "dose": "200 mcg", "notes": "GH pulse for sleep & recovery.", "route": "subcutaneous", "schedule": "pre-sleep, 5 days/wk", "substance_slug": "ipamorelin" } ], "parent_protocol_id": null, "version": 1, "created_at": "2026-05-20T13:34:51.641198+00:00" }, { "id": "f4a7d85a-8027-44b6-8b7b-4e78f98c53f2", "slug": "hailey-glow-stack", "name": "Glow & longevity stack", "tagline": "Skin peptides + longevity pulse — aligned with the \"glazed donut\" routine.", "stack": [ { "dose": "2 mg", "notes": "Copper peptide for skin & hair.", "route": "subcutaneous", "schedule": "daily, 8 weeks", "substance_slug": "ghk-cu" }, { "dose": "10 mg", "notes": "Telomere/longevity pulse.", "route": "subcutaneous", "schedule": "daily, 10 days, 2x/year", "substance_slug": "epitalon" }, { "dose": "topical 10%", "notes": "Topical wrinkle-relax peptide.", "route": "topical", "schedule": "daily", "substance_slug": "argireline" } ], "parent_protocol_id": null, "version": 1, "created_at": "2026-05-20T13:34:51.641198+00:00" }, { "id": "d97e5ed8-60f3-428b-bfc5-de4f9c2df1ac", "slug": "mounjaro-foodnoice-fh-protocol", "name": "Mounjaro Foodnoice FH protocol", "tagline": "No more Sugar cravings at night", "stack": [ { "dose": "7.5 mg", "notes": "Mounjaro — Eli Lilly. \nUse in morning\nTrainig in evenig\nTip A\nTip B\nTip C\n\nTest.... FH protocol", "route": "subq", "schedule": "weekly", "substance_slug": "tirzepatide" } ], "parent_protocol_id": null, "version": 1, "created_at": "2026-07-14T21:30:06.17307+00:00" }, { "id": "737127cc-e421-4c28-8261-83d0e1958857", "slug": "bryan-johnson-blueprint", "name": "Blueprint longevity", "tagline": "Multi-peptide longevity protocol from Project Blueprint.", "stack": [ { "dose": "10 mg", "notes": "Telomere & circadian pulse.", "route": "subcutaneous", "schedule": "daily, 20 days, quarterly", "substance_slug": "epitalon" }, { "dose": "10 mg", "notes": "Mitochondrial peptide.", "route": "subcutaneous", "schedule": "2x weekly", "substance_slug": "mots-c" }, { "dose": "1.6 mg", "notes": "Immune modulation.", "route": "subcutaneous", "schedule": "2x weekly", "substance_slug": "thymosin-alpha-1" }, { "dose": "2 mg", "notes": "Skin & systemic repair.", "route": "subcutaneous", "schedule": "daily", "substance_slug": "ghk-cu" }, { "dose": "5 mg", "notes": "Mitochondrial cardiolipin-targeting peptide.", "route": "subcutaneous", "schedule": "daily", "substance_slug": "ss-31" } ], "parent_protocol_id": null, "version": 1, "created_at": "2026-05-20T13:34:51.641198+00:00" } ], "forkEdges": [ { "parent_protocol_id": "aaaaaaaa-0000-0000-0000-000000000001", "child_protocol_id": null, "created_at": "2026-05-19T07:57:45.550437+00:00" }, { "parent_protocol_id": "aaaaaaaa-0000-0000-0000-000000000001", "child_protocol_id": null, "created_at": "2026-05-19T07:57:45.550437+00:00" }, { "parent_protocol_id": "aaaaaaaa-0000-0000-0000-000000000001", "child_protocol_id": null, "created_at": "2026-05-19T07:57:45.550437+00:00" }, { "parent_protocol_id": "aaaaaaaa-0000-0000-0000-000000000002", "child_protocol_id": null, "created_at": "2026-05-19T07:57:45.550437+00:00" }, { "parent_protocol_id": "aaaaaaaa-0000-0000-0000-000000000003", "child_protocol_id": null, "created_at": "2026-05-19T07:57:45.550437+00:00" }, { "parent_protocol_id": "aaaaaaaa-0000-0000-0000-000000000003", "child_protocol_id": null, "created_at": "2026-05-19T07:57:45.550437+00:00" }, { "parent_protocol_id": "aaaaaaaa-0000-0000-0000-000000000003", "child_protocol_id": null, "created_at": "2026-05-20T12:48:14.147965+00:00" }, { "parent_protocol_id": "e32912ae-ffca-4be5-9f69-da62bcadc356", "child_protocol_id": null, "created_at": "2026-05-20T18:34:07.007659+00:00" }, { "parent_protocol_id": "737127cc-e421-4c28-8261-83d0e1958857", "child_protocol_id": null, "created_at": "2026-05-30T18:57:07.995007+00:00" }, { "parent_protocol_id": "f4a7d85a-8027-44b6-8b7b-4e78f98c53f2", "child_protocol_id": null, "created_at": "2026-05-30T20:24:53.217924+00:00" }, { "parent_protocol_id": "e32912ae-ffca-4be5-9f69-da62bcadc356", "child_protocol_id": null, "created_at": "2026-05-30T20:26:28.168189+00:00" }, { "parent_protocol_id": "e32912ae-ffca-4be5-9f69-da62bcadc356", "child_protocol_id": null, "created_at": "2026-06-03T12:29:59.866907+00:00" }, { "parent_protocol_id": "e32912ae-ffca-4be5-9f69-da62bcadc356", "child_protocol_id": null, "created_at": "2026-07-14T20:10:10.28958+00:00" } ], "followEvents": [ { "target_handle": "adachen", "source": "direct", "created_at": "2026-05-19T07:55:57.574428+00:00" }, { "target_handle": "adachen", "source": "quiz", "created_at": "2026-05-19T07:55:57.574428+00:00" }, { "target_handle": "adachen", "source": "card", "created_at": "2026-05-19T07:55:57.574428+00:00" }, { "target_handle": "adachen", "source": "search", "created_at": "2026-05-19T07:55:57.574428+00:00" }, { "target_handle": "marco", "source": "direct", "created_at": "2026-05-19T07:55:57.574428+00:00" }, { "target_handle": "marco", "source": "subdomain", "created_at": "2026-05-19T07:55:57.574428+00:00" }, { "target_handle": "lena", "source": "quiz", "created_at": "2026-05-19T07:55:57.574428+00:00" }, { "target_handle": "lena", "source": "direct", "created_at": "2026-05-19T07:55:57.574428+00:00" }, { "target_handle": "lena", "source": "card", "created_at": "2026-05-19T07:55:57.574428+00:00" }, { "target_handle": "adachen", "source": "direct", "created_at": "2026-05-19T07:57:45.550437+00:00" }, { "target_handle": "adachen", "source": "quiz", "created_at": "2026-05-19T07:57:45.550437+00:00" }, { "target_handle": "adachen", "source": "card", "created_at": "2026-05-19T07:57:45.550437+00:00" }, { "target_handle": "adachen", "source": "search", "created_at": "2026-05-19T07:57:45.550437+00:00" }, { "target_handle": "marco", "source": "direct", "created_at": "2026-05-19T07:57:45.550437+00:00" }, { "target_handle": "marco", "source": "subdomain", "created_at": "2026-05-19T07:57:45.550437+00:00" }, { "target_handle": "lena", "source": "quiz", "created_at": "2026-05-19T07:57:45.550437+00:00" }, { "target_handle": "lena", "source": "direct", "created_at": "2026-05-19T07:57:45.550437+00:00" }, { "target_handle": "lena", "source": "card", "created_at": "2026-05-19T07:57:45.550437+00:00" }, { "target_handle": "adachen", "source": "direct", "created_at": "2026-05-20T12:47:56.586765+00:00" }, { "target_handle": "haileybieber", "source": "direct", "created_at": "2026-05-21T19:28:39.86777+00:00" }, { "target_handle": "clavicular", "source": "direct", "created_at": "2026-07-14T12:05:07.44126+00:00" }, { "target_handle": "joerogan", "source": "protocol", "created_at": "2026-07-14T20:10:16.801099+00:00" }, { "target_handle": "marco", "source": "direct", "created_at": "2026-07-21T08:41:57.967027+00:00" } ], "adverseEvents": [ { "substance_slug": "semaglutide", "product_slug": "compounded-semaglutide-2mg", "severity": "mild", "narrative": "Mild nausea for first 48 hours after first dose, resolved by day 3. No other symptoms.", "created_at": "2026-05-19T07:55:57.682173+00:00" }, { "substance_slug": "semaglutide", "product_slug": "compounded-semaglutide-2mg", "severity": "mild", "narrative": "Mild nausea for first 48 hours after first dose, resolved by day 3. No other symptoms.", "created_at": "2026-05-19T07:57:45.550437+00:00" }, { "substance_slug": "bpc-157", "product_slug": "peptide-sciences-bpc-157-5mg", "severity": "mild", "narrative": "Mild redness at injection site for 2-3 hours. No systemic symptoms across 8-week cycle.", "created_at": "2026-05-19T07:55:57.682173+00:00" }, { "substance_slug": "bpc-157", "product_slug": "peptide-sciences-bpc-157-5mg", "severity": "mild", "narrative": "Mild redness at injection site for 2-3 hours. No systemic symptoms across 8-week cycle.", "created_at": "2026-05-19T07:57:45.550437+00:00" }, { "substance_slug": "tirzepatide", "product_slug": "unverified-tirzepatide-vial", "severity": "moderate", "narrative": "Persistent tachycardia (resting HR 95-100) starting day 4. Discontinued at week 2. Resolved within 5 days.", "created_at": "2026-05-19T07:55:57.682173+00:00" }, { "substance_slug": "tirzepatide", "product_slug": "unverified-tirzepatide-vial", "severity": "moderate", "narrative": "Persistent tachycardia (resting HR 95-100) starting day 4. Discontinued at week 2. Resolved within 5 days.", "created_at": "2026-05-19T07:57:45.550437+00:00" } ], "quizResponsesAnon": [ { "quiz_slug": "find-your-recovery-stack", "matched_protocol_ids": [ "aaaaaaaa-0000-0000-0000-000000000001" ], "created_at": "2026-05-19T07:57:45.550437+00:00" }, { "quiz_slug": "find-your-recovery-stack", "matched_protocol_ids": [ "aaaaaaaa-0000-0000-0000-000000000003", "aaaaaaaa-0000-0000-0000-000000000004" ], "created_at": "2026-05-19T07:57:45.550437+00:00" }, { "quiz_slug": "find-your-recovery-stack", "matched_protocol_ids": [ "aaaaaaaa-0000-0000-0000-000000000002" ], "created_at": "2026-05-19T07:57:45.550437+00:00" }, { "quiz_slug": "find-your-recovery-stack", "matched_protocol_ids": [ "aaaaaaaa-0000-0000-0000-000000000001", "aaaaaaaa-0000-0000-0000-000000000002" ], "created_at": "2026-05-19T07:57:45.550437+00:00" }, { "quiz_slug": "find-your-recovery-stack", "matched_protocol_ids": [ "aaaaaaaa-0000-0000-0000-000000000002" ], "created_at": "2026-05-19T08:02:36.152641+00:00" } ], "auditLog": [ { "action": "adverse_event.filed", "subject_kind": "adverse_event", "subject_id": "07b7b4f9-0681-4887-88ba-4c7e797457d0", "created_at": "2026-05-19T07:57:45.550437+00:00" }, { "action": "adverse_event.filed", "subject_kind": "adverse_event", "subject_id": "1ad4862d-a8d6-4da4-9f45-867f72e3eaca", "created_at": "2026-05-19T07:57:45.550437+00:00" }, { "action": "adverse_event.filed", "subject_kind": "adverse_event", "subject_id": "aba2a521-2088-4a1d-9112-c99f28094227", "created_at": "2026-05-19T07:57:45.550437+00:00" }, { "action": "adverse_event.filed", "subject_kind": "adverse_event", "subject_id": "65622efe-22dd-4ddc-96fa-20f566a90021", "created_at": "2026-05-19T07:57:45.550437+00:00" }, { "action": "adverse_event.filed", "subject_kind": "adverse_event", "subject_id": "eca81301-3d2b-48e6-a2c7-f9d554f2d482", "created_at": "2026-05-19T07:57:45.550437+00:00" }, { "action": "adverse_event.filed", "subject_kind": "adverse_event", "subject_id": "310ae705-04f5-44e9-9ed0-3578054008c2", "created_at": "2026-05-19T07:55:57.682173+00:00" }, { "action": "adverse_event.filed", "subject_kind": "adverse_event", "subject_id": "b61f0e50-9e91-4ff6-ac88-aa1f71929069", "created_at": "2026-05-19T07:55:57.682173+00:00" }, { "action": "adverse_event.filed", "subject_kind": "adverse_event", "subject_id": "fccbdccf-0fb3-4864-b68d-ad5fe9b061e9", "created_at": "2026-05-19T07:55:57.682173+00:00" }, { "action": "adverse_event.filed", "subject_kind": "adverse_event", "subject_id": "92d8a244-e656-484a-bd3d-567343aab3a4", "created_at": "2026-05-19T07:55:57.682173+00:00" }, { "action": "adverse_event.filed", "subject_kind": "adverse_event", "subject_id": "b18ed299-9522-4a4e-ac6f-5a9e92bb5a7a", "created_at": "2026-05-19T07:55:57.682173+00:00" } ] }